Latest technologies from Canberra IP

Isoform-selective HDAC inhibitors

ttoinfo@wayne.edu — Tue, 16 Jun 2026 17:03:16 GMT

Selective C4-modified SAHA analogs inhibit HDAC6 and HDAC8 enzymes for targeted therapeutic applications.

Technology Summary

Histone deacetylase (HDAC) proteins are key players in cancer progression and have emerged recently as targets for anti-cancer drugs. WSU researchers have synthesized a variety of small molecule HDAC inhibitors and evaluated their potencies. This technology involves the design, synthesis, and characterization of C4-modified suberoylanilide hydroxamic acid (SAHA) analogs that selectively inhibit histone deacetylase enzymes HDAC6 and HDAC8. These enzymes play key roles in the progression of diseases such as cancer, and selective inhibition allows for improved therapeutic efficacy with reduced side effects.

Key Advantages

High selectivity for HDAC6 and HDAC8 enzymes reduces off-target effects
Detailed synthesis procedures for reproducible compound production
Demonstrated efficacy in modulating biological activity related to cell viability
Dual inhibitors targeting both HDAC6 and HDAC8

Market Opportunities

Research tools for studying HDAC6/8 enzyme functions
Pharmaceutical development of selective HDAC inhibitors
Novel Inhibitor development and substrate identification for next generation Cancer therapeutics

Stage of Development

Pre-Clinical

Patent Status

Issued US patent 10,259,779

References & Publications

Negmeldin, et al. 2018, Europ J Med Chem, 143, 1790-1806

https://doi.org/10.1016/j.ejmech.2017.10.076

Peptide Linkers for Modulating Antigen Immune Response in Cancer Vaccines

dragos@northwestern.edu — Tue, 16 Jun 2026 16:53:13 GMT

SHORT DESCRIPTION

A novel non-biologically derived peptide linker technology enabling precise intracellular release of vaccine antigens to enhance immune activation.

INVENTORS

Chad Mirkin*
- Weinberg College of Arts and Sciences, Department of Chemistry
Tanner Fink

* Principal Investigator

NU TECH ID

NU 2024-124

IP STATUS

Pending

THERAPEUTICS DEVELOPMENT STAGE

Target Validation

Preclinical efficacy PoC (small animals)

BACKGROUND

Current peptide-based cancer vaccines have shown unsatisfactory results in clinical trials due to low immunogenicity. Existing technologies fail to ensure effective intracellular antigen release resulting in limited T-cell activation. Many approaches rely on chemically labile linkers that cannot adequately preserve antigen structure during release. An unmet need exists for a method that can control antigen processing to overcome these limitations and improve vaccine performance.

ABSTRACT

Northwestern researchers have developed a specially designed non-biological peptide sequence that, when conjugated to peptide antigens, enables controlled, spatial, and temporal intracellular release via cleavage by the endosomal protease Cathepsin S. The technique ensures that antigens are released in their unmodified, and therefore their most immunogenic, state. In vitro and in vivo studies demonstrate robust immune activation, suggesting significant potential for advancing peptide-based cancer vaccines. This technology overcomes the limitations of current cancer vaccines by improving the delivery and immunogenicity of peptide antigens delivered through nanoparticle-based vaccine formulations.

APPLICATIONS

Cancer immunotherapy: Enhances antigen processing to promote targeted immune responses in cancer immunotherapy.
Nanoparticle vaccine formulations: Enables controlled intracellular release for improved vaccine efficacy.
Development of peptide-based vaccines.
Immunoengineering and precision medicine.

ADVANTAGES

Enhances immune activation: Achieves more robust T-cell responses compared to conventional methods.
Controls antigen release: Provides precise spatial and temporal control of intracellular antigen release and maintains antigen integrity.
Improved stability and immunogenicity of peptide antigens by avoiding premature degradation.
Versatile platform: Compatible with various nanoparticle-based vaccine formulations, including spherical nucleic acid vaccine platforms.
Addresses unmet clinical need: Overcomes limitations of low immunogenicity in peptide-based vaccines.

PUBLICATIONS

N/A

KEYWORDS

Peptide linkers, cancer vaccine, immune activation, nanoparticle vaccine, antigen processing, Cathepsin S, peptide-based vaccine, immunotherapy

Cell permeable ATP analogs

ttoinfo@wayne.edu — Tue, 16 Jun 2026 16:30:29 GMT

A novel ATP analog featuring a polyamine linker enables efficient kinase-catalyzed biotinylation within live cells by enhancing cell permeability.

Technology Summary

ATP (adenosine 5’-triphosphate) analogs such as ATP-biotin are widely used to monitor biochemical events in vitro. WSU researchers developed a specially designed ATP analog that replaces the conventional PEG linker with a positively charged polyamine linker, significantly improving cell permeability. This advancement allows the ATP analog to enter live cells and participate in kinase-catalyzed biotinylation, enabling detailed study of protein kinases and their substrates in physiologically relevant conditions. Experimental validation demonstrates successful intracellular protein labeling, overcoming the limitations of traditional ATP-biotin which is restricted to in vitro use. The invention supports enhanced research into cell signaling pathways critical to diseases such as cancer and diabetes.

Key Advantages

Enhanced cell permeability.
Improves labeling efficiency and physiological relevance of protein interaction studies.
Enables real-time study of kinase activity and substrate interactions inside living cells.
Detailed chemical variations and synthesis methods for application flexibility.

Market Opportunities

Facilitates advanced research into signaling pathways and disease mechanisms.
Biochemical and molecular biology research focused on kinase function.
Cell signaling pathway analysis in kinase-related diseases including cancer, diabetes, and others.
Development of diagnostic tools based on kinase activity and protein labeling.

Stage of Development

Pre-Clinical.

Patent Status

Issued US patent 10,429,397

References & Publications

Fouda 2015, Angew Chem Int Ed. 54(33), 9618-21

https://doi.org/10.1002/anie.201503041

Biomimetic HDL Nanoparticles for Treatment of Cancer, Immune and Inflammatory Disorders, and Cardiovascular Disease

dragos@northwestern.edu — Tue, 16 Jun 2026 16:08:47 GMT

SHORT DESCRIPTION
Self-assembling biomimetic high-density lipoprotein nanoparticle (HDL NP) platform technology with a soft organic core, designed to more closely replicate key functional properties of mature human HDL for therapeutic use in cardiovascular disease, cancer, and inflammatory/immune disorders.

INVENTORS

Colby Thaxton*
- Northwestern University Feinberg School of Medicine, Department of Urology

* Principal Investigator

NU Tech ID: NU 2023-068, NU 2023-167

IP STATUS
Multiple US Patents Pending (19/486,837; 19/512,420)

DEVELOPMENT STAGE
TRL-5 – Experimental Proof-of-Concept: In vitro cell-based assays and in vivo murine models confirm efficacy.

BACKGROUND
HDL particles play central roles in reverse cholesterol transport, shuttling cholesterol out of macrophages and other cells to the liver, and also exert anti‑inflammatory and immunomodulatory effects that are relevant to atherosclerosis, cancer, and chronic inflammatory disease. Clinically, higher levels and preserved function of HDL, particularly spherical subclasses, are associated with lower risk of atherosclerotic cardiovascular disease and may influence tumor biology via cholesterol metabolism and scavenger receptor class B type I (SR‑BI) signaling. Multiple synthetic and reconstituted HDL (rHDL) approaches have been evaluated for drugs delivery and plaque regression but have shown mixed clinical results, in part because they do not fully reproduce the structure and dynamic cholesterol‑handling capabilities of mature spherical HDL or require inorganic templates such as gold cores. At the same time, cancer and inflammatory therapies increasingly exploit SR‑BI‑targeted HDL‑like nanoparticles to deliver chemotherapeutics, nucleic acids, or imaging agents to tumors, but many current platforms face constraints around core composition, cholesterol flux, and scalability. This creates a clear unmet need for next‑generation HDL mimetics that better match native spherical HDL in size, soft‑core architecture, cholesterol transport, and anti‑inflammatory functions, and that can be flexibly loaded with therapeutic or diagnostic payloads while retaining favorable biophysical properties.

ABSTRACT

Northwestern researchers have developed novel synthetic spherical HDL‑NPs comprising a lipid‑conjugated organic dendritic core scaffold surrounded by a phospholipid shell, optionally bearing apolipoprotein A‑I. The organic core is built from small multifunctional molecules such as pentaerythritol or sorbitol that are conjugated to defined fatty acid or PEG‑fatty acid moieties (for example PE‑S4, PE‑O4, Sorb(PEG)‑S6, Sorb(PEG)‑O6), enabling tunable control of particle size, charge, and softness while supporting 3‑D supramolecular assembly of HDL‑like particles. The resulting organic core HDL‑NPs (oc-HDL NPs) have hydrodynamic diameters in the approximate 8–20 nm range and negative zeta potentials similar to human HDL, show efficient association with cholesterol and cholesteryl esters, and exhibit enhanced cholesterol efflux from macrophages and delivery to hepatocytes compared with apolipoprotein alone or gold‑templated HDL mimetics. In cellular models, these oc‑HDL NPs also reduce NF‑κB and JNK signaling and decrease inflammatory readouts in macrophage‑derived cell lines, supporting their potential as anti‑inflammatory agents in cardiovascular and immune disease. Additionally, through various in vitro and in vivo studies on prostate cancer (PCa), cutaneous T-cell lymphoma (CTCL), and AML models, the inventors have demonstrated the ability of oc-HDL NPs to target SR-BI on cancer cells, deliver therapeutic agents, and activate pathways to induce cell death via ferroptosis, apoptosis, and pyroptosis. Moreover, the inventors also synthesized two novel lipid molecules containing gold salts, DPPTE-AuPEt3 and cholS-AuPEt3 and showed that in a psoriasis-like murine model of imiquimod (IMQ)-induced skin inflammation, topical application of gold-containing oc-HDL NPs improves the skin phenotype, normalizes SR-B1 expression, and reduces molecular and cellular markers of inflammation. These data indicate the strong potential of HDL-NPs as targeted therapies for cancer, inflammatory diseases, and bacterial diseases capable of enhancing therapeutic efficacy with lower drug doses and minimize side effects compared to conventional therapies.

APPLICATIONS

Targeted drug‑delivery platform for SR‑BI‑expressing cancers (e.g. breast, prostate, renal cell, and neuroblastoma): Delivery of chemotherapeutics, nucleic acids, or phototherapeutics into HDL‑NPs to reduce dosing, improve tumor uptake, and reduce off‑target toxicity.
Treatment of inflammatory and immune‑mediated diseases by leveraging the HDL‑NPs’ intrinsic anti‑inflammatory effects (NF‑κB/TNF‑α reduction) and/or by delivering anti‑inflammatory small molecules or nucleic acids in chronic inflammatory or autoimmune settings.
Treatment and prevention of atherosclerotic cardiovascular disease and related vascular conditions by enhancing reverse cholesterol transport, reducing macrophage foam‑cell burden, and suppressing vascular inflammation.
Combination cardio‑oncology or cardio‑metabolic strategies in patients with overlapping dyslipidemia, ASCVD risk, and cancer, using HDL‑NPs as a modular vehicle to simultaneously address both vascular biology and tumor targeting.
Research and translational tools for dissecting HDL structure–function relationships, validating targets in reverse cholesterol transport and inflammation, and rapidly prototyping HDL‑based nanocarriers with varying core and shell compositions

ADVANTAGES

Improved targeting: Delivers therapy directly to affected sites, reducing systemic exposure.
High potency: Demonstrates therapeutic effects at low nanomolar doses.
Enhanced safety: Minimizes side effects compared to conventional high-dose gold salt treatments.
Modular design: Offers a versatile platform that can be tuned for multiple therapeutic applications.
Versatile payload compatibility: Supports incorporation or surface attachment of a broad range of therapeutic agents, including chemotherapeutics, nucleic acids, antioxidants, and anti‑inflammatory drugs, and can exploit SR‑BI‑mediated direct cytosolic delivery to tumor cells
Broad-spectrum therapeutic: Applicable across cardiovascular, oncology, inflammatory/immune, and potentially sepsis and bone‑disease indications

PUBLICATIONS

Lavker RM et al., Synthetic high-density lipoprotein nanoparticles: Good things in small packages. Ocul Surf. July 2021
Rink JS et al., Encapsulation and Delivery of the Kinase Inhibitor PIK-75 by Organic Core High-Density Lipoprotein-Like Nanoparticles Targeting Scavenger Receptor Class B Type 1. ACS Appl Mater Interfaces. Jan 8, 2025.
Lamperis SM et al., CRISPR screen reveals a simultaneous targeted mechanism to reduce cancer cell selenium and increase lipid oxidation to induce ferroptosis. Proc Natl Acad Sci USA . Jun 3, 2025.
Lin AY et al., Targeting scavenger receptor class B type 1 with a bioinspired ligand induces apoptosis or ferroptosis in AML.Blood Neoplasia. Jun 3, 2025.
Trujillo J et al., Keratinocyte SR-B1 expression and targeting in cytokine-driven skin inflammation. Commun Med (Lond). Apr 3, 2025.

CATEGORY/INDUSTRY PIPELINE
Therapeutics; Healthcare Devices, Tools & IT; Biomarkers and Biomedical Research Tools

KEYWORDS
HDL nanoparticles, targeted therapy, drug delivery, inflammation, immunology, oncology, cancer, cardiovascular, nanoparticle, nanomaterials, biomimetics, lipid conjugates, targeted drug delivery, nanomedicine

Protein Degraders of NSD2 for Targeted Treatment of Head and Neck Cancers

dragos@northwestern.edu — Tue, 16 Jun 2026 16:07:37 GMT

SHORT DESCRIPTION
Targeted protein degraders that selectively eliminate NSD2 for improved treatment of head and neck cancers.

INVENTORS

Gary Schiltz*
- Weinberg College of Arts and Sciences, Department of Chemistry
Yanis Boumber

* Principal Investigator

NU Tech ID: NU 2023-140

IP STATUS

U.S. Patent Pending

DEVELOPMENT STAGE

TRL-4 - Prototype Validated in Lab: Laboratory-scale models have demonstrated key functionalities, showing effective degradation of NSD2 in cancer cell lines.

BACKGROUND
Head and neck cancers collectively account for more than 660,000 new cases and 325,000 deaths worldwide each year, with laryngeal carcinoma representing roughly 30–40% of these malignancies and about 185,000 cases and 100,000 deaths annually. Laryngeal cancer (LC) is particularly impactful because it threatens both survival and core functions such as voice, swallowing, and airway protection. In the U.S., localized disease carries a 5‑year survival of ~80%, but survival drops to ~50% with nodal spread and ~35% with distant metastases, and global outcomes are worse in low‑resource settings. Current treatments combine surgery (ranging from endoscopic laser resection to total laryngectomy), radiation, and platinum‑based chemoradiotherapy, and while early‑stage disease can often be controlled with single‑modality radiotherapy or organ‑preserving surgery, advanced tumors frequently require multimodal therapy or laryngectomy, leading to permanent tracheostomy, loss of natural voice, dysphagia, chronic aspiration risk, and substantial quality‑of‑life impairment. Even with modern chemoradiation and organ‑preserving approaches, many patients experience local recurrence, long‑term dysphonia and swallowing dysfunction, and high rates of unmet supportive‑care needs. underscoring a persistent unmet need for more effective, larynx‑sparing therapies that maintain oncologic control while better preserving function and reducing late toxicity.

ABSTRACT
Recent reports indicate that loss-of-function mutations in histone methyltransferases NSD1 and NSD2 occur in roughly 20% of LC cases that define a novel prognostic subtype associated with dramatically extended overall survival. Northwestern researchers have leveraged these findings and developed a series of small molecule degraders that selectively target the NSD2 protein, a protein crucial for tumor cell viability in head and neck squamous cell carcinomas, including LC. The molecules are designed to induce the proteolysis of NSD2 by recruiting an E3 ubiquitin ligase, disrupting oncogenic signaling pathways more effectively than traditional enzymatic inhibitors. Preliminary laboratory studies demonstrate that degrading the entire NSD2 protein produces a more profound effect in reducing cancer cell proliferation and inducing apoptosis. The technology offers a novel and promising pathway toward improved treatments for head and neck squamous cell carcinomas, laryngeal carcinoma, and other NSD2-driven cancers.

APPLICATIONS

Head and neck squamous cell carcinomas: Provides a novel targeted treatment option aimed at malignant cells.
Laryngeal carcinoma: Offers a novel therapeutic strategy for patients with aggressive LC and limited treatment options.
Other cancers: Potentially applicable to cancers where NSD2 plays a critical role in tumor survival.

ADVANTAGES

Novel mechanism of action: Provides an innovative treatment approach where traditional therapies fall short.
Overcomes limitations of traditional enzymatic inhibition: Degrading the entire NSD2 protein yields more potent effects on tumor cell viability.
Enhances therapeutic efficacy: Targets a critical oncogenic pathway to potentially improve patient outcomes.
Broad applicability: offer a novel treatment for other cancers driven by NSD2 activity.

PUBLICATIONS

N/A

Kinase blocking inhibition in cancer

IEA@rfsuny.org — Tue, 16 Jun 2026 15:38:45 GMT

This technology introduces novel compositions and methods using mutated forms of TIMP-2 to precisely regulate extracellular MMP-2 activity, offering targeted control over tissue remodeling processes.

Background:
Matrix metalloproteinase-2 (MMP-2) plays a vital role in remodeling the extracellular matrix, which is essential for normal physiological functions such as tissue repair. However, its dysregulation is strongly linked to pathological conditions, including cancer metastasis and other diseases characterized by abnormal tissue degradation. Conventional methods for controlling MMP-2 activity have lacked specificity and efficacy, creating a need for innovative strategies that modulate this enzyme in a targeted manner. This need inspired research into the regulation of MMP-2 by tissue inhibitors of metalloproteinases, particularly focusing on modifications through phosphorylation to achieve better control.

Technology Overview:
This invention centers on the use of engineered TIMP-2 mutants that selectively alter the activity of extracellular MMP-2 by modifying phosphorylation sites on TIMP-2. These mutants are designed either to enhance or inhibit MMP-2 activity, depending on therapeutic requirements. By targeting the phosphorylation events that regulate TIMP-2’s interaction with MMP-2, the technology enables fine-tuning of enzyme activity rather than complete inhibition, which is a novel approach compared to existing broad-spectrum inhibitors. The technology is supported by detailed biochemical studies demonstrating how specific amino acid changes in TIMP-2 influence MMP-2 function. Experimental data validate that these mutants can effectively regulate the enzymatic activity in vitro, providing a controlled mechanism to adjust extracellular matrix remodeling processes. This targeted modulation holds the promise of addressing diseases where excessive or insufficient MMP-2 activity contributes to disease progression, such as cancer and fibrotic disorders. The ability to selectively enhance or inhibit MMP-2 expands therapeutic options, potentially reducing side effects associated with non-specific metalloproteinase inhibition.

https://suny.technologypublisher.com/files/sites/adobestock_1828918781.jpeg
Photo for reference only, not a depiction of the invention.

Advantages:
•   Precise modulation of MMP-2 activity through targeted phosphorylation site mutations on TIMP-2.
•   Potential to both enhance and inhibit MMP-2, providing flexible therapeutic strategies.
•   Reduced likelihood of off-target effects compared to non-specific metalloproteinase inhibitors.
•   Novel biochemical approach enabling regulation rather than complete suppression of enzyme activity.
•   Supported by experimental evidence validating efficacy and mechanism of action.

Applications:
•   Treatment of cancers where MMP-2 contributes to tumor invasion and metastasis through extracellular matrix degradation.
•   Therapies for fibrotic diseases involving abnormal tissue remodeling and matrix deposition.
•   Potential use in controlled wound healing processes by regulating tissue repair through MMP-2 activity.
•   Research tools for studying extracellular matrix dynamics and metalloproteinase regulation in various pathological contexts.

Intellectual Property Summary:
Patented: 12,006,351
https://patents.google.com/patent/US12006351B2/en

Stage of Development:
TRL 3 – Experimental Proof of Concept

Licensing Status:
This technology is available for licensing.

Targeting Protein Phosphatase-5 in Cancer

IEA@rfsuny.org — Tue, 16 Jun 2026 15:30:26 GMT

This technology introduces a novel approach to cancer treatment by targeting Protein Phosphatase 5 (PP5) to regulate apoptosis and inhibit tumor growth, particularly in clear cell renal cell carcinoma (ccRCC).

Background:
Cancer cells often evade programmed cell death, allowing tumors to grow unchecked. In clear cell renal cell carcinoma, dysregulation of key signaling pathways disrupts apoptosis, contributing to cancer progression. Protein Phosphatase 5 (PP5), a serine/threonine phosphatase, has been found to interact with proteins involved in the extrinsic apoptotic pathway, modulating cell survival. Understanding and manipulating this mechanism opens promising avenues for cancer therapy.

Technology Overview:
The invention focuses on PP5’s critical role in cancer cell survival by dephosphorylating and inactivating proteins that trigger apoptosis, such as caspase-8, FADD, and RIPK1. PP5 maintains the integrity of Complex II, a molecular assembly essential for initiating programmed cell death. The technology introduces a specific inhibitor named P-53, which blocks substrate binding to PP5, thereby preventing its anti-apoptotic action. Inhibition of PP5 by P-53 leads to increased apoptotic activity in VHL-null ccRCC cells, restoring the natural pathway for cell death and suppressing tumor growth. This targeted therapy offers a precise mechanism to selectively induce cancer cell apoptosis without affecting healthy cells, making it a potentially effective treatment for renal cancer and other malignancies with similar pathways.

https://suny.technologypublisher.com/files/sites/adobestock_1041788413.jpeg
Photo for reference only, not a depiction of the invention.

Advantages:
•   Selective targeting of PP5 provides a focused therapeutic approach that minimizes damage to normal cells.
•   Restores the natural apoptotic process in cancer cells, overcoming resistance to cell death.
•   Potentially effective against clear cell renal cell carcinoma, especially VHL-null tumor types which are typically difficult to treat.
•   Novel mechanism of action that differs from conventional chemotherapies, offering new treatment options.
•   Supported by a robust scientific understanding of PP5’s role in apoptosis and cancer signaling pathways.

Applications:
•   Treatment of clear cell renal cell carcinoma through targeted apoptosis induction.
•   Potential application in other cancers where PP5-mediated dephosphorylation disrupts apoptotic pathways.
•   Development of new cancer therapeutics based on PP5 inhibition as a mechanism to trigger tumor cell death.
•   Research tool for studying PP5’s role in cancer biology and apoptotic regulation.

Intellectual Property Summary:
Patent application filed: 18/873,996
https://patents.google.com/patent/US20250360108A1/en

Stage of Development:
TRL 3 – Experimental Proof of Concept

Licensing Status:
This technology is available for licensing.

Injectable Bioactive Hydrogels for Targeted Vascular Growth and Tissue Repair

saradagen@ufl.edu — Tue, 16 Jun 2026 12:45:10 GMT

Triggers Localized Angiogenesis by Self-Assembling DNA-Aptamer-Collagen Matrices Without External Growth Factors

This injectable bioactive hydrogel induces angiogenesis locally by self-assembling DNA-aptamer-collagen matrices without external growth factors. Angiogenesis, the formation of new blood vessels from preexisting vasculature, supports tissue repair, regeneration, and oxygen delivery. While tightly regulated under normal physiological conditions, impaired or insufficient angiogenesis is a major barrier to healing in chronic wounds, ischemic tissues, and degenerative conditions. Current pro-angiogenic strategies primarily rely on recombinant growth factors such as vascular endothelial growth factor (VEGF), which suffer from rapid degradation, high cost, short half-life, and off-target effects, while cell-based therapies raise issues of immune compatibility, scalability, and regulatory complexity. Therefore, there is an evident need for an injectable platform that provides a sustained, biomimetic pro-angiogenic microenvironment while meeting the growing demand for safe, localized, and cost-effective angiogenic therapies in regenerative medicine. The global tissue engineering and regenerative medicine market continues to expand rapidly, as the global market size was valued at USD 19.36 billion in 2024 and is projected to grow to USD 43.13 billion by 2030.

Researchers at the University of Florida developed an injectable hydrogel platform for inducing localized angiogenesis. The system is built from nucleic acid-collagen complexes (NACCs), a novel class of biomaterials formed through the self-assembly of type I collagen and single-stranded DNA (ssDNA). In this platform, NACCs are functionalized with a DNA aptamer designed to activate vascular endothelial growth factor receptor 2 (VEGFR-2), a key regulator of angiogenic signaling. By eliminating the need for exogenous growth factors or cell transplantation, this aptamer-functionalized hydrogel system represents a promising and scalable solution for promoting vascularization and tissue repair.

Application

This injectable hydrogel platform induces localized delivery of pro-angiogenic signals in regenerative medicine, including applications in wound healing, ischemic tissue repair, and tissue engineering scaffolds

Advantages

Promotes host tissue integration and neovascularization, accelerating healing through rapid cell infiltration and scaffold remodeling
Triggers VEGFR-2 signaling without the need for recombinant proteins, reducing cost and improving stability
Self-assembles into injectable hydrogel, allowing minimally invasive administration via standard needles for precise, localized treatment
Provides enhanced biocompatibility and stability, protecting embedded aptamers from degradation while minimizing systemic inflammation and immune response

Technology

The platform consists of an injectable hydrogel formed through the self-assembly of type I collagen and single-stranded DNA, creating nucleic acid-collagen complexes (NACCs) with integrated biological functionality. The system is functionalized with a VEGFR-2-activating DNA aptamer that selectively binds and stimulates receptor signaling pathways critical for angiogenesis. Upon injection, the hydrogel exhibits shear-thinning behavior, enabling minimally invasive delivery while maintaining structural integrity at the target site. Within the matrix, the collagen scaffold supports endothelial cell adhesion, proliferation, and three-dimensional organization, while the embedded aptamer promotes receptor-mediated vascular signaling. The hydrogel protects the aptamer from nuclease degradation, ensuring sustained bioactivity in physiological environments. This platform supports localized vascular remodeling, host cell infiltration, and new blood vessel formation without the need for exogenous growth factors or cell transplantation. Compatible with in vivo and in vitro applications, the technology provides a programmable, biocompatible system for promoting angiogenesis and advancing regenerative medicine strategies.

Gene Therapy for Leber Congenital Amaurosis

nihott@nih.gov — Tue, 16 Jun 2026 07:58:51 GMT

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an AAV gene therapy for Leber Congenital Amaurosis caused by CEP290 mutations.

This technology includes an innovative gene therapy approach for treating Leber congenital amaurosis (LCA) caused by CEP290 mutations. LCA is a severe inherited eye disorder that leads to significant vision loss in infants, affecting approximately 20,000 individuals worldwide. Currently, there are no effective treatments available for LCA, particularly for the CEP290 mutation, which accounts for 20-25% of cases. Our research has identified a functional subunit of the CEP290 gene that can be effectively delivered to the retina using an adeno-associated viral (AAV) vector, overcoming the limitations of previous gene therapy attempts that struggled with the large size of the full-length CEP290 gene. This breakthrough offers hope for restoring vision in patients suffering from this debilitating condition.

Innovative Gene Therapy for Retinal Diseases

nihott@nih.gov — Tue, 16 Jun 2026 07:51:51 GMT

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative gene therapy for retinal diseases.

This technology includes an innovative gene therapy approach aimed at treating retinal diseases, which are a leading cause of vision loss. Retinal diseases, such as age-related macular degeneration and retinitis pigmentosa, affect millions of people worldwide and currently have limited treatment options. Our gene therapy targets the underlying genetic causes of these diseases, offering a potential cure rather than just symptomatic relief.

The technical solution involves the use of adeno-associated virus (AAV) vectors to deliver therapeutic genes directly to retinal cells. This method is significant because it not only addresses the root cause of the disease but also has the potential for long-lasting effects, reducing the need for frequent treatments. You should care about this technology because it represents a breakthrough in the field of ophthalmology, with the potential to restore vision and improve the quality of life for patients suffering from debilitating retinal conditions.

We are seeking licensing partners who are interested in co-developing this groundbreaking technology. The ideal partner would have experience in gene therapy and a commitment to advancing innovative treatments in ophthalmology. We are open to discussions regarding collaboration and are eager to explore opportunities that align with our goals for this technology.

Advanced Gene Editing Technology for Therapeutic Applications

nihott@nih.gov — Tue, 16 Jun 2026 07:51:04 GMT

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of advanced gene editing technology for therapeutic applications.

This technology includes advanced gene editing techniques aimed at developing targeted therapies for genetic disorders. Current treatments for many genetic conditions are limited, often resulting in lifelong management rather than a cure. This technology offers a precise and efficient method to modify genes, potentially correcting the underlying causes of these disorders. By utilizing cutting-edge CRISPR technology, this solution not only enhances the accuracy of gene editing but also minimizes off-target effects, making it a safer option for therapeutic use. Stakeholders in the healthcare and biotechnology sectors should care about this technology as it represents a significant advancement in the pursuit of curative treatments for previously untreatable conditions. The licensing opportunity for this technology is open for collaboration with industry partners who are interested in further developing and commercializing these innovative therapeutic solutions. We are looking for partners who can contribute to the next stages of development and bring these therapies to market.

Stable Cell Line for Large Scale Production of Human Retinoschisin for Ocular Therapy

nihott@nih.gov — Tue, 16 Jun 2026 07:50:47 GMT

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a stable cell line for the production of human Retinoschisin (RS1) for therapeutic applications in ocular diseases.

This technology includes the development of a stable cell line for the large-scale production of human Retinoschisin (RS1), a protein crucial for retinal health, which has potential therapeutic applications for X-Linked Retinoschisis (XLRS). XLRS is a genetic condition that leads to severe vision loss due to the malfunction of the RS1 protein. Current treatment options are limited, and this technology aims to provide a novel approach by producing RS1 in a human cell line, ensuring proper post-translational modifications and reducing immunogenicity. The stable cell line, derived from ARPE-19 cells, allows for consistent and high-yield production of RS1, which can be utilized for both therapeutic and research purposes.

The technical solution involves the use of human ARPE-19 cells, which are known for their ability to produce and secrete proteins effectively. This cell line has been optimized to express RS1 and its variants, including mutant forms, under serum-free conditions, which is essential for therapeutic applications. The significance of this technology lies in its potential to improve patient outcomes for those suffering from XLRS by providing a reliable source of RS1 for treatment.

The licensing opportunity for this technology is open for collaboration with industry partners interested in ocular therapeutics. The inventors are seeking partners who can assist in further development and commercialization of the RS1 protein and its delivery systems, including encapsulated cell-based therapies and nanoparticle formulations for targeted delivery to the retina.

Immunosuppressive Exosomes for Treating Autoimmune Diseases

nihott@nih.gov — Tue, 16 Jun 2026 07:50:26 GMT

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of immunosuppressive exosomes derived from IL-35 and IL-27 producing Bregs as a therapeutic treatment for autoimmune diseases.

This technology includes the use of exosomes derived from Interleukin 35 (IL-35) and Interleukin 27 (IL-27) producing regulatory B cells (Bregs) as a therapeutic treatment for autoimmune diseases such as uveitis and multiple sclerosis. Current therapies face challenges with dosing and bioavailability of IL-35, which is a weakly associated heterodimer that can easily dissociate. Our innovative approach utilizes exosomes that encapsulate both subunits of IL-27 and IL-35, ensuring a stable and effective delivery mechanism. This advancement addresses the critical need for reliable dosing and bioavailability in immunotherapy, making it a significant improvement over existing treatments.

The technical solution involves the isolation and application of exosomes that contain biologically active IL-27 and IL-35, which have shown efficacy in preclinical models by suppressing neuroinflammation and promoting regulatory immune responses. This technology is particularly relevant for C-level executives and directors in the biotech and pharmaceutical industries, as it opens new avenues for treating challenging autoimmune conditions with a novel delivery system that overcomes existing barriers in therapeutic administration.

We are seeking licensing opportunities for this groundbreaking technology, which has the potential to transform the treatment landscape for autoimmune diseases. Collaborators and licensees will benefit from access to a unique therapeutic platform that is ready for further development and commercialization. We invite interested parties to engage in discussions regarding potential partnerships and licensing agreements to bring this innovative therapy to market.

Myocilin Mutant Cell Lines for Glaucoma Research and Drug Screening

nihott@nih.gov — Tue, 16 Jun 2026 07:50:11 GMT

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative therapeutic strategies targeting myocilin mutations in glaucoma.

This technology includes the development of HEK293 cell lines expressing wild-type and Y437H mutant myocilin, which can be used to study the pathogenic mechanisms of glaucoma and screen for therapeutic agents. Glaucoma, a leading cause of blindness, is often associated with mutations in the myocilin gene, but the exact mechanisms by which these mutations lead to cell death are not fully understood. By utilizing these cell lines, researchers can investigate how mutant myocilin induces endoplasmic reticulum stress and apoptosis, particularly under oxidative stress conditions. This understanding could pave the way for the development of targeted therapies that mitigate the effects of these mutations and improve patient outcomes.

Mini-Bioreactor for Enhanced Organoid Culture

nihott@nih.gov — Tue, 16 Jun 2026 07:49:54 GMT

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a mini-bioreactor designed to enhance organoid culture outcomes.

This technology includes a mini-bioreactor designed to improve organoid outcomes in cell culture applications. The bioreactor system is a multi-well, 3D-printed device that fits standard 100 mm cell culture dishes and utilizes a central stirring mechanism to create a controlled laminar flow. This innovative design addresses the common challenges in organoid culture, such as non-specific adherence and fusion, while enhancing mass transfer without the shear stress typically associated with other bioreactor systems.

The technical solution provided by this bioreactor is significant because it simplifies the organoid culture process by integrating a single-component system that is compatible with standard lab equipment. This means that researchers can easily adopt this technology without needing specialized training or additional components. The ability to track individual organoids longitudinally further enhances its utility in research settings, making it an attractive option for laboratories focused on organoid studies.

The licensing opportunity for this technology is promising, as it can be developed and produced in less than two years. Companies that manufacture cell culture vessels, such as Corning, Thermo Fisher, and VWR, may find this bioreactor particularly appealing for their product lines. Collaboration with the inventors is encouraged to explore the full commercial potential of this innovative bioreactor system.

A Robust Method to Generate Macular vs Peripheral RPE Cells for Cell Therapy and Drug Discovery

nihott@nih.gov — Tue, 16 Jun 2026 07:49:24 GMT

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a robust method to generate macular and peripheral retinal pigment epithelium (RPE) cells for targeted therapies and drug discovery.

This technology includes a robust method to generate macular and peripheral retinal pigment epithelium (RPE) cells, which are crucial for developing targeted cell therapies and drug discovery for retinal degenerative diseases. The problem lies in the lack of in vitro models that accurately reproduce the regional diversity and vulnerability of RPE cells, particularly in conditions like age-related macular degeneration (AMD) and retinitis pigmentosa. Our innovative approach utilizes two specific drugs, AGN 193109 and endo-IWR 1, to induce distinct macular and peripheral RPE phenotypes from induced pluripotent stem cells (iPSCs), enabling the study of regional RPE defects and high-throughput drug screening for specific retinal conditions.

The technical solution leverages the unique properties of iPSC-derived RPE cells, which can be manipulated to reflect the diverse characteristics of human RPE. This is significant because it allows researchers and clinicians to better understand the mechanisms underlying retinal diseases and to develop targeted therapies. By creating a high-throughput platform for generating various RPE cell types, we can facilitate the discovery of disease-specific pathways and drug candidates, ultimately leading to improved treatment options for patients suffering from retinal degenerative diseases.

We are seeking licensing opportunities for this technology, which has the potential to revolutionize the field of retinal research and therapy. Collaborators and licensees will benefit from access to a cutting-edge platform that addresses a critical gap in current RPE research and therapeutic development. We are open to discussions regarding potential partnerships and collaborations to further advance this technology.

Biodegradable Tissue Scaffold for Multi-Tissue Transplantation

nihott@nih.gov — Tue, 16 Jun 2026 07:48:39 GMT

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a biodegradable tissue scaffold designed for multi-tissue transplantation.

This technology includes a dual-layer biodegradable tissue scaffold designed for the transplantation of multiple tissue types, such as retinal pigment epithelium (RPE) and photoreceptors. The current challenge in tissue transplantation is the lack of mechanical strength in existing scaffolds, which often leads to separation during handling and implantation. This innovative scaffold addresses these issues by utilizing a unique structure made from poly(lactic-co-glycolic acid) (PLGA) that combines a lower support layer with a secondary matrix of lactide-rich loops, enhancing stability and facilitating cell adhesion and polarization.

The technical solution involves a temperature-fused design that creates a robust scaffold with minimal capillary forces, allowing for better integration of the two tissue layers. This is particularly important for complex eye surgeries where multiple tissues are affected. By providing a supportive environment for weakly adherent cells, this scaffold can significantly improve the outcomes of retinal and choroidal transplants, making it a valuable tool for restoring vision in patients with advanced eye diseases.

The licensing opportunity for this technology is open for collaboration with industry partners interested in advancing tissue engineering and transplantation techniques. The inventor seeks partnerships that can help bring this innovative scaffold to market, focusing on its application in regenerative medicine and ophthalmology.

RPGR Gene Therapy for Retinitis Pigmentosa

nihott@nih.gov — Tue, 16 Jun 2026 07:48:08 GMT

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of RPGR gene therapy for Retinitis Pigmentosa.

This technology includes an abbreviated version of the RPGR gene that is effective in gene replacement therapy for treating X-linked Retinitis Pigmentosa (XLRP). This condition is a genetic disorder that leads to progressive vision loss due to the degeneration of photoreceptor cells in the retina. The current version of RPGR is known to be unstable and can undergo changes in vivo, which may be harmful to recipient cells. The abbreviated RPGR retains its function, rescues the disease, and is stabilized, making it a safer option for gene therapy.

The technical solution involves using an adeno-associated viral vector that carries the abbreviated human RPGR cDNA. This vector supplies functional RPGR proteins to treat inherited ocular disorders related to RPGR mutations. This technology is significant because it addresses the instability issues of the current RPGR gene therapy approaches, providing a more reliable and effective treatment option for patients suffering from XLRP. Stakeholders in the ophthalmology and gene therapy fields should care about this innovation as it represents a potential breakthrough in treating a debilitating condition.

The licensing opportunity for this technology is open for collaboration with interested parties who are looking to develop and commercialize this gene therapy. The inventors are seeking partners who can assist in further development and potential market entry, ensuring that this promising therapy reaches those in need.

Detection of Organomercurial Compound Biosynthesis in Microbial Communities

nihott@nih.gov — Tue, 16 Jun 2026 07:47:08 GMT

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative detection methods for organomercurial biosynthesis in microbial communities.

This technology includes a novel method for detecting organomercurial compound biosynthesis, which poses significant health risks due to mercury contamination. Current detection methods primarily focus on the HgcAB system, which is limited in scope and effectiveness. Our approach leverages sequence-based techniques to identify a new family of radical SAM proteins that are likely involved in the formation of organomercurials through an unknown mechanism. This advancement allows for a more comprehensive and accurate identification of mercury-methylating organisms, which is crucial for assessing environmental and health risks.

The technical solution involves the construction of a hidden Markov model (HMM) named NF040546, which serves as a search tool to identify members of this novel enzyme family. This is important because it opens new avenues for understanding microbial mercury methylation pathways, which have been inadequately characterized by existing methods. By improving detection capabilities, this technology can significantly enhance environmental monitoring and public health safety, making it a valuable asset for researchers and industries concerned with mercury contamination.

We are seeking licensing opportunities for this technology, which has the potential to be developed into commercial products or services aimed at environmental monitoring and health risk assessment. Collaborators or licensees can expect to engage in a mutually beneficial partnership that leverages our innovative detection methods and their applications in various fields, including agriculture and public health.

Targeted Disruption of Rpe65 Gene for Retinal Disease Research

nihott@nih.gov — Tue, 16 Jun 2026 07:46:36 GMT

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a targeted disruption of the Rpe65 gene in mice, a novel model for studying retinal diseases and testing potential therapies.

This technology includes the targeted disruption of the Rpe65 gene in mice, which serves as a crucial model for studying inherited retinal diseases and testing potential therapies. The RPE65 protein is essential for converting dietary vitamin A into the 11-cis isomer, a vital component for vision. The absence of this protein in our mouse model leads to a complete lack of 11-cis retinoids, resulting in blindness, thus confirming its role in the visual cycle. This innovative genetic strategy not only provides insights into the biochemical processes of vision but also opens avenues for developing treatments for RPE65-related retinal disorders.

The technical solution involves creating a genetically modified mouse model that lacks the Rpe65 gene, allowing researchers to observe the resulting phenotype and understand the implications of RPE65 mutations in human diseases. This model is particularly valuable for pharmaceutical companies and research institutions focused on ocular health, as it enables the testing of new drugs and therapies aimed at restoring vision in patients with RPE65 mutations. By utilizing this model, stakeholders can accelerate the development of effective treatments for retinal diseases, ultimately benefiting patients suffering from vision loss.

We are seeking licensing opportunities for this groundbreaking technology, which has already garnered interest from companies such as Acucela Inc. Collaborators can expect a mutually beneficial partnership that leverages our expertise in genetic engineering and retinal biology to advance therapeutic solutions. Licensing this technology will provide access to a unique research tool that can significantly impact the field of ophthalmology and vision science.

Snapwell Shipping Container for Live Cell Cultures

nihott@nih.gov — Tue, 16 Jun 2026 07:45:33 GMT

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a novel shipping container designed to protect live cell cultures during transport.

This technology includes a specialized container designed for the secure shipping of fragile cell cultures grown on the Snapwell insert system, preventing media splashing that can damage the cells. The problem this invention addresses is the lack of reliable shipping options for sensitive tissues that cannot be frozen, which are increasingly used in tissue transplantation applications. Current methods do not adequately protect these tissues during transport, leading to potential damage and loss of viability.

The technical solution involves a series of thermo-molded inserts placed within standard 50ml containers, which create smaller protective compartments around the living cells. This design minimizes the movement of surrounding media, thereby reducing the risk of damage to the cell layer. This innovation is particularly relevant for academic institutions, biotechnology companies, and military applications, all of which are exploring new tissue transplantation technologies and require dependable shipping solutions.

We are seeking licensing opportunities for this technology, which has the potential for significant impact in the transplantation field. The prototype is ready for testing in research settings, and we are open to collaboration with partners interested in commercializing this invention.

iPSC Differentiation Protocol for Fibroblast and Endothelial Cell Generation

nihott@nih.gov — Tue, 16 Jun 2026 07:44:37 GMT

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a novel iPSC differentiation protocol for generating fibroblasts and endothelial cells.

This technology includes a novel protocol for differentiating induced pluripotent stem cells (iPSCs) into fibroblasts and endothelial cells, which are crucial for tissue engineering and regenerative medicine applications. Current methods for generating these cell types can be inefficient and inconsistent, leading to challenges in research and therapeutic applications. This protocol aims to streamline the differentiation process, enhancing the yield and quality of the derived cells.

The technical solution leverages optimized culture conditions and growth factors to promote the efficient differentiation of iPSCs into fibroblasts and endothelial cells. This is significant because it addresses the growing demand for reliable and reproducible cell sources in research and clinical settings. By providing a standardized method, this technology can facilitate advancements in tissue engineering, drug testing, and regenerative therapies.

The licensing opportunity for this technology is open to partnerships with companies and research institutions interested in cell therapy, regenerative medicine, and related fields. Collaborators can expect to engage in co-development efforts to further refine and commercialize the protocol, ensuring its applicability in various biomedical applications.

Thermosensitive Hydrogel Bioink for Vascular Tissue Engineering

nihott@nih.gov — Tue, 16 Jun 2026 07:44:11 GMT

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for a thermosensitive, pro-angiogenic material designed for 3D bioprinting.

This technology includes a thermosensitive hydrogel bioink designed for vascular tissue engineering. The hydrogel is unique in that it transitions from a gel state at room temperature to a liquid state at physiological temperatures, allowing for easy handling and application in bioprinting. The primary challenge in tissue engineering is the formation of functional blood vessels, which is critical for tissue viability. Current methods often involve harmful chemical crosslinkers or UV light, which can compromise cell viability. This hydrogel, made from fibrinogen and gelatin, promotes blood vessel formation by providing a supportive extracellular matrix without the use of harmful agents.

The technical solution involves a combination of fibrinogen, which serves as a provisional extracellular matrix, and gelatin, which adjusts viscosity with temperature changes. This innovative approach not only enhances cell viability but also reduces material costs, making it a compelling option for researchers and companies in the field of tissue engineering. You should care about this technology because it represents a significant advancement in bioprinting techniques, enabling the creation of vascularized tissues that closely mimic natural environments.

The licensing opportunity for this technology is open to interested parties looking to collaborate in further development or commercialization. The inventors are seeking partners who can help bring this innovative bioink to market, potentially leading to groundbreaking applications in regenerative medicine and tissue engineering.

Interferon Gamma for Retinal Fluid Absorption Restoration

nihott@nih.gov — Tue, 16 Jun 2026 07:43:44 GMT

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of Interferon gamma as a therapeutic agent to restore retinal fluid absorption.

This technology includes the use of Interferon gamma to restore fluid absorption in retinal pigment epithelial (RPE) cells, specifically targeting the adverse effects of fluid accumulation under the retina caused by small molecule cancer therapeutic drugs like Meki. The problem arises when cancer treatments, particularly MAP Kinase/ERK Kinase Inhibitors, lead to unwanted fluid build-up, which can impair vision and overall retinal health. This technology addresses a significant challenge in ocular health by providing a potential therapeutic solution to mitigate these side effects of cancer treatment.

The technical solution involves leveraging the previously established method of fluid transport across RPE cells, enhanced by the application of Interferon gamma. This approach not only aims to alleviate fluid accumulation but also seeks to improve the overall efficacy of cancer therapies by minimizing their ocular side effects. You should care about this technology because it represents a novel intersection of oncology and ophthalmology, potentially improving patient outcomes for those undergoing cancer treatment.

Currently, the National Eye Institute (NEI) is seeking collaborative support to fund or provide a source of Interferon gamma for larger clinical trials. There is an opportunity for licensing this technology, especially as NEI is in discussions with potential partners, including a start-up and Merck, to further clinical trials related to this innovative approach. This presents a unique chance for collaboration and investment in a promising therapeutic avenue.

Interferon Gamma as a Therapeutic Agent for Proliferative Eye Diseases

nihott@nih.gov — Tue, 16 Jun 2026 07:43:14 GMT

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of Interferon-gamma as a therapeutic agent for proliferative eye diseases.

This technology includes the use of Interferon-gamma (IFN-y) as a therapeutic agent to inhibit the proliferation and migration of human retinal pigment epithelial (RPE) cells, which is crucial in treating proliferative eye diseases such as age-related macular degeneration and proliferative vitreoretinopathy. The problem at hand is that abnormal RPE cell behavior is linked to severe ocular diseases that can lead to vision loss, affecting millions of individuals, particularly the elderly. The inventors have discovered that IFN-y can significantly reduce this abnormal cell activity, providing a potential treatment pathway for these debilitating conditions.

The technical solution involves intraocular injections of IFN-y, which have shown promise in halting excessive RPE proliferation and migration, thereby preventing the formation of abnormal tissues in the eye. This technology is important because it addresses a significant unmet medical need in ophthalmology, offering a novel approach to managing diseases that currently have limited treatment options. By targeting the underlying cellular mechanisms, this therapy could improve patient outcomes and reduce the burden of vision loss associated with these conditions.

The licensing opportunity for this technology is aimed at pharmaceutical companies and research institutions interested in developing new treatments for ocular diseases. The inventors are seeking partners for co-development and commercialization, emphasizing the potential for collaborative efforts to bring this innovative therapy to market. This collaboration could involve further clinical trials and research to validate the efficacy and safety of IFN-y in treating proliferative eye diseases.

Calcineurin Inhibitor-Antibody Conjugates for Targeted Treatment of Th17 Driven Inflammatory Diseases

nihott@nih.gov — Tue, 16 Jun 2026 07:38:50 GMT

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of calcineurin inhibitor-antibody conjugates aimed at treating Th17 driven inflammatory diseases.

This technology includes calcineurin inhibitor-antibody conjugates designed for the targeted treatment of Th17 driven inflammatory diseases, such as autoimmune and allergic conditions. The problem this technology addresses is the ineffectiveness of traditional treatments for certain patients, particularly those with steroid-resistant diseases, due to the overactivity of Th17 cells that produce the pro-inflammatory cytokine IL-17. By utilizing antibody-drug conjugates, this invention aims to deliver calcineurin inhibitors directly to these problematic immune cells, enhancing treatment efficacy and minimizing side effects.

The technical solution involves conjugating calcineurin inhibitors, which are known immunosuppressants, to antibodies that specifically target CCR6, a receptor found on Th17 cells. This targeted approach is significant because it allows for the selective suppression of IL-17 production in these cells, potentially leading to better outcomes for patients suffering from conditions like multiple sclerosis, rheumatoid arthritis, and uveitis. You should care about this technology because it represents a novel method of treating diseases that currently have limited therapeutic options, thereby addressing a critical public health need.

The licensing opportunity for this technology is promising, as it has been developed in collaboration with the University of Bristol, which is eager to coordinate efforts for patent protection and commercialization. The inventors are looking for partners interested in further developing this innovative approach to treatment, and they are open to discussions regarding licensing agreements that would facilitate the advancement of this technology into clinical applications.

AI Based Workflow for Single Cell Analysis

nihott@nih.gov — Tue, 16 Jun 2026 07:37:23 GMT

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for single-cell RNA sequencing (scRNA-seq) analysis software that leverages existing large language models (LLM) to simplify and enhance data analysis by providing intelligent recommendations and interpretations.

This technology includes SCassist, an innovative open-source R package designed to enhance single-cell RNA sequencing (scRNA-seq) data analysis. The complexity of scRNA-seq workflows often requires extensive expertise, making it challenging for many researchers to fully explore their data. This limitation can hinder scientific discovery and innovation, as researchers may struggle to navigate through the intricate stages of data filtering, normalization, clustering, and interpretation. SCassist addresses these challenges by leveraging large language models (LLMs) to provide intelligent recommendations and interpretations throughout the analysis process, making advanced scRNA-seq analysis accessible to researchers at all levels.

SCassist integrates LLMs into key workflow steps, offering guidance on filtering, normalization, clustering parameters, and insightful interpretations of variable features and principal components. It also performs cell type annotations and provides a system-level view through network representations based on pathway and ontology enrichment analyses. This user-friendly interface allows researchers to incorporate AI-driven insights into their scRNA-seq analysis, ultimately accelerating their workflow and uncovering deeper biological understanding. By democratizing scRNA-seq analysis, SCassist empowers researchers to navigate complexities and make the most of their valuable data.

The National Eye Institute (NEI) is seeking licensing opportunities and collaborative partnerships to further develop and expand the capabilities of SCassist. This technology has the potential to be utilized across various fields, including genomics, proteomics, and metabolomics, enabling researchers to gain novel insights into their ‘omics’ scale data. The NEI welcomes inquiries from potential partners interested in leveraging SCassist to enhance their research capabilities and drive scientific innovation.

Modular System for Battery Thermal Management

jhayden@ndsurf.org — Mon, 15 Jun 2026 20:04:30 GMT

This innovative Battery Thermal Management System (BTMS) leverages a modular and scalable design approach to enhance thermal regulation of batteries in electric vehicles. Through a combination of computational fluid dynamics modeling and experimental validation, the system efficiently maintains optimal battery temperatures under varying flow and discharge conditions. Two prototypes were tested, with the single-inlet design demonstrating superior thermal performance and ease of maintenance, making it ideal for commercial applications.

Benefits

Modular and scalable design enabling easy customization and maintenance
Enhanced thermal performance validated through both simulation and physical testing
Efficient temperature control reducing battery overheating and extending battery lifespan
Simplified design with single-inlet approach for improved operational efficiency
Validated under a variety of flow rates and discharge scenarios

Applications

Thermal management solutions for electric vehicle battery packs
Battery cooling systems in electric motorcycles, cars, and commercial EV fleets
Modular thermal management integration for battery manufacturers and automotive OEMs
Research and development platforms for improving battery system efficiency and safety

Patents

This technology is patent pending in the US and is available for licensing/partnering opportunities.

Engineering Asymmetrically Glycosylated IgG Antibodies

emoryott@inteummail.com — Mon, 15 Jun 2026 19:26:46 GMT

Application

A method to produce asymmetrically glycosylated antibodies for the treatment and prevention of diseases including cancer, auto-immune disorders, and infectious diseases.

Key Benefits

This strategy has potential to produce a new class of therapeutic antibodies for treating and preventing a wide range of human diseases.

Market Summary

Monoclonal antibodies are widely used therapeutics for treating diseases such as cancer, autoimmune disorders, degenerative conditions, and inflammation. Despite their impact, they face limitations, including difficulty targeting intracellular or “undruggable” proteins and modulating protein–protein interactions. Immunoglobulin G (IgG), which accounts for 70–75% of circulating antibodies, mediates immune responses through interactions between its Fc region and Fc gamma receptors (FcγRs) on immune cells, leading to activating or inhibitory effects. Recent studies have shown that asymmetrically glycosylated IgG antibodies, or those antibodies with distinct glycans on each of their two Fc region protomers, are a universal and prevalent feature of human immunology that drive distinctive antibody-mediated effector functions. Accordingly, methods to engineer asymmetrically glycosylated antibodies will produce a new class of IgG antibodies with precisely controlled effector functions and improved therapeutic performance.

Technical Summary

Inventors at Emory University have developed methods to produce asymmetrically glycosylated IgG antibodies that can represent a new class of therapeutic monoclonal antibodies for the treatment or prevention of a disease. The proposed strategy can be expanded to engineer any possible combination of asymmetrically glycosylated IgG antibodies. Antibodies generated using the proposed method could result in proteins with unique therapeutic potential.

MTHFD2-Targeting Peptide Decoy for Chemotherapy-Resistant Cancers

emoryott@inteummail.com — Mon, 15 Jun 2026 19:21:20 GMT

Application

An engineered decoy peptide, DMp39, targeting DLAT-MTHFD2 interaction, as a sensitizer for chemotherapy resistant cancer treatment.

Key Benefits

Restores chemotherapy sensitivity in resistant tumors.
Targets the DLAT-MTHFD2 pathway with high specificity and minimal off-target toxicity.

Market Summary

Chemotherapy resistance remains a major barrier to effective cancer treatment, driving disease progression and limiting long-term patient outcomes. Emerging evidence links dysregulated protein acetylation to resistance mechanisms, though the underlying molecular pathways are not yet fully defined. At the same time, demand is increasing for targeted therapies that act rapidly and selectively, particularly in oncology. Peptide-based therapeutics are gaining traction as a promising modality, supported by advances in precision medicine and biomarker-driven treatment strategies. Within this evolving landscape, there is a significant unmet need for approaches that can restore chemotherapy sensitivity through novel mechanisms. Targeting mitochondrial pathways represents a compelling and underexplored opportunity to overcome resistance. Innovations that address these challenges have the potential to redefine treatment paradigms for resistant cancers and improve patient response to existing therapies.

Technical Summary

Emory researchers have developed DMp39, a cell-permeable decoy peptide designed to overcome chemotherapy resistance in cancer. It works by disrupting a newly discovered interaction between two mitochondrial proteins, DLAT and MTHFD2, that drives chemotherapy resistance. Blocking DLAT-mediated acetylation of MTHFD2 at lysine-44 with DMp39 restores sensitivity to cisplatin and promotes cancer cell death with minimal toxicity offering a promising new class of peptide-based cancer therapeutics.

Development Stage

In vitro and in vivo study results available.
The inventors have synthesized a more stable analog of the peptide and are evaluating it in combination with multiple chemotherapy and immunotherapy agents to determine optimal treatment strategies for cancer.

Publication Hwang, J. S., Kang, J., Kim, J., Eun, K., West, S., Bacho, H. E., Avalos, V., Shuff, S., Shin, D. M., Saba, N. F., Magliocca, K. R., Qu, C. K., Fu, H., Ramalingam, S. S., Ivanov, A. A., Hitosugi, T., & Kang, S. (2025). Non-canonical dihydrolipoyl transacetylase promotes chemotherapy resistance via mitochondrial tetrahydrofolate signaling. *Nature Communications, 16*, 8932. https://doi.org/10.1038/s41467-025-63892-3

Targeting Hypoxia-inducible factor 2alpha in cancer

IEA@rfsuny.org — Mon, 15 Jun 2026 19:11:24 GMT

This technology offers a novel approach for new cancer treatments based on inhibiting HIF2α-related processes.

Background:
Hypoxia-inducible factor 2α (HIF2α) transcription factor is involved in the adaptation of cancer cells (including clear cell renal cell carcinoma (ccRCC)) to low oxygen conditions (hypoxia). It plays a role in promoting tumor growth and angiogenesis. Pharmacologic inhibition of HIF2α offers a novel therapeutic strategy for cancers driven by HIF2α signaling. Belzutifan, a highly specific and well-tolerated HIF2α inhibitor, recently received FDA approval for the treatment of nonmetastatic renal cell carcinomas, pancreatic neuroendocrine tumors, and central nervous system hemangioblastomas from patients with von Hippel-Lindau disease, who carry VHL germline mutations.

Technology Overview:
This technology is a selective HIF2α inhibitor that has a different mode of action compared to Belzutifan. It works by disrupting the binding of HIF2α from its molecular chaperone Hsp70. Additionally, this HIF2α inhibitor may potentially combat Belzutifan resistance in cancer patients. Compound-c2 binds to the PAS-B domain of HIF2α and disrupts its interaction with the molecular chaperone Heat shock protein-70 (Hsp70). This leads to proteasomal degradation of HIF2α and activation of apoptosis in ccRCC. This offers a promising alternative for addressing drug resistance and presents a unique approach to inhibiting HIF2α-related processes.

https://suny.technologypublisher.com/files/sites/adobestock_535202789.jpeg
Photo for reference only, not a depiction of the invention.

Advantages:
• Offers a promising alternative for addressing Belzutifan drug resistance.
• Provides a unique approach in inhibiting HIF2α-related processes.

Applications:
The primary application for this technology is developing cancer treatments.

Intellectual Property Summary:
Patent pending

Stage of Development:
TRL 3 – Experimental proof of concept

Flexible Nanophotonic Cavity-Enhanced Infrared Photodetectors Employing Double Quantum Wells

techtransfer@buffalo.edu — Mon, 15 Jun 2026 18:59:08 GMT

Double-quantum-well infrared photodetectors (DQWIPs) integrated with nanophotonic cavities enable highly responsive mid-infrared detection through enhanced intersubband absorption in the thin semiconductor heterostructure. Additionally, the technology is compatible with flexible substrates.

Background:

Quantum Well Infrared Photodetectors (QWIPs) are sensitive photodetectors for the mid-to-long-wave infrared spectrum (3-20 µm) that are often used in applications such as remote sensing, imaging, and optical communications. In recent years, QWIP technologies have undergone substantial development, with the most recent introduction of single-quantum-well infrared photodetectors (SQWIP). While SQWIPs exhibit increased responsivity and detectability compared to earlier QWIPs, the structure of SQWIP devices can result in a degradation of photocurrent, decreasing responsivity. This technology provides a novel Quantum Well Infrared Photodetector, which utilizes two quantum wells, resulting in state-of-the-art responsivity performance with the capacity to be implemented on flexible substrates.

Technology Overview:

This University at Buffalo technology features a novel Double Quantum Well Infrared Photodetector, which exhibits state-of-the-art detector responsivity performance, substantially improving upon earlier QWIP technologies, including SQWIP. Additionally, our DQWIP technology is sufficiently thin such that it can be used on flexible substrates, opening up a wide variety of novel applications.

https://buffalo.technologypublisher.com/files/sites/7646_inpart_image.jpg

luchschenF, https://stock.adobe.com/203302012, stock.adobe.com

Advantages:

Superior device performance with higher responsivity and detectivity.
Mechanical flexibility of these devices will enable a broad range of new applications.
Highly tailorable operating wavelength range.
Lower costs associated with the semiconductor heterostructure growth.

Applications:

Conventional-format flat and rigid QWIPs and based focal plane arrays with superior performances;
Flexible infrared photodetectors for wearable devices, sensors and systems;
Concave-curved infrared focal plane arrays for wide field-of-view cameras/imagers;
Convex-curved infrared focal plane arrays for compound-eye type compact low-weight imagers.

Intellectual Property Summary:

PCT/US2026/031312 filed June 4, 2026.

Stage of Development:

Prototypes fabricated and validated within the laboratory setting.
TRL 5

Licensing Status:

Available for licensing or collaboration.

Reduction of Lipid Accumulation Reverses Aging

techtransfer@buffalo.edu — Mon, 15 Jun 2026 18:51:24 GMT

Therapeutic strategy to treat age-related cardiovascular disease and restore cardiovascular function through maintenance of lipid homeostasis.

Background:

Age is a key risk factor for cardiovascular disease such as atherosclerosis, which is characterized by endothelial dysfunction, extracellular matrix remodeling, lipid accumulation, chronic inflammation and increased ferroptosis. However, there is currently no effective therapeutic that directly targets the cellular and metabolic drivers of vascular aging. Most interventions delay progression but do not reverse the aging phenotype at the molecular level. This technology offers a therapeutic strategy to treat age-related cardiovascular disease and restore cardiovascular function.

Technology Overview:

This University at Buffalo technology uncovers a previously unrecognized regulator of vascular aging. Loss of molecular expression in aged vascular cells is associated with impaired lipid oxidation, excessive lipid accumulation and increased ferroptosis. Knockdown models in young endothelial cells (EC) and vascular smooth muscle cells (VSMC) induced hallmark features of aging, including DNA damage, impaired proliferation, and ferroptotic stress. These mice show symptoms of premature aging, including progressive weight loss, abnormal posture and marked curvature of the spine and significantly shorter life-span (103 days as compared to more than 2 years for the wild-type mice). They also exhibit significant cardiovascular problems and accelerated skeletal muscle aging. Therapeutic treatment successfully restored lipid homeostasis, suppressed ferroptosis and reversed age-related hallmarks, such as expression of senescence-associated beta-galactosidase, decreased DNA damage, decreased inflammation, and improved overall function in both in vitro and in vivo models. Furthermore, studies observed significantly improved extracellular matrix (ECM) integrity and arterial endothelial function. This technology provides a therapeutic agent for age-related cardiovascular disease through restoration of vascular lipid homeostasis.

https://buffalo.technologypublisher.com/files/sites/7690_in-part_image.jpg

Source: Rasi, https://stock.adobe.com/uk/305362371, stock.adobe.com

Advantages:

Increased myofiber size
Increased body weight
Increased ambulatory time and distance
Enhanced muscle regeneration after injury
Expanded ability of muscle to generate force (twitch and tetanic forces)
Improved activity of arterial eNOS, the enzyme responsible for nitric oxide production and vasodilation for improved blood flow
Improved ECM composition, e.g., collagen and elastin, within aged arteries
Increased lipid oxidation in mitochondria
Decreased lipid accumulation in aged arteries and muscle
Increased autophagy

Applications:

Therapeutic use
Clinical progress monitoring
Research tool

Intellectual Property Summary:

PCT/US2026/029715 filed May 26, 2026

Stage of Development:

Completion of in vitro and in vivo studies in mouse models.

Licensing Status:

Available for licensing or collaboration.

ALD-enabled High-Performance Membranes for Gas Separation

techtransfer@buffalo.edu — Mon, 15 Jun 2026 18:48:00 GMT

Polymer-based membranes developed with high H₂/CO₂ selectivity using facile surface nanoengineering for higher energy efficiency and lower cost production.

Background:

Isolation of CO₂ from mixtures containing H₂ is a critical gas separation, producing 94 million metric tons of H₂ worldwide and valued at $170 billion in 2021. This market will continue to grow with added regulations on CO₂ production from increased international pressure for cleaner energy and reduced emissions, as exemplified in the Integrated Gasification Combined Cycle processes and the Net Zero by 2050 Initiative. These processes all produce more H₂ and require increased CO₂ capture, so improvements in H₂/CO₂ separation efficiency lead directly to significant savings in H₂ generation and power production. Here, increased gas separation efficiency is provided through atomic layer deposition (ALD) technology to create customized polymer membranes, achieving advanced separations at low cost and higher energy efficiency.

Technology Overview:

This University at Buffalo invention provides an innovative approach to gas separation membranes using ALD-enabled facile surface nanoengineering to design polymer-based membranes for H₂/CO₂ separation. The thermally stable membrane shows high H₂permeability and high H₂/CO₂ selectivity, leading to a low cost and energy efficient separation of hydrogen purification and CO₂ capture from fossil fuel-derived power plants. Additionally, these membranes can operate at the syngas processing temperature (150°C). Unlike the conventional absorption or adsorption technology operating near ambient temperatures, the membrane technology developed here shows high energy efficiency and low operating cost.

https://buffalo.technologypublisher.com/files/sites/7551_in-part_image.jpg

Source: creativenature.nl, https://stock.adobe.com/uk/144767717, stock.adobe.com

Advantages:

Conventional competitive methods operate at 10°C or below, while these membranes operate up to 200°C and maintain thermal stability
High H₂ permeability
High CO₂/H₂selectivity
High energy efficiency
Low operating cost

Applications:

Hydrogen separation and carbon capture from hydrogen purification plants
Carbon dioxide capture from fossil fuel-derived power plants
Syngas purification for methanol plants
Hydrogen recovery from refinery off-gas and natural gas liquid production
Hydrogen recovery from mixtures with nitrogen in ammonia plants
Separation of hydrogen from mixtures with helium

Intellectual Property Summary:

US National Patent Application 19/589,374 filed on May 21, 2026.

Stage of Development:

Laboratory demonstration through in vitro studies and analytical chemical analysis.

Licensing Status:

Available for licensing or collaboration.

Relevant Links:

Small molecule inhibition of SHIP1 induces broad activation of natural killer cells

IEA@rfsuny.org — Mon, 15 Jun 2026 18:40:32 GMT

This technology involves methods to activate natural killer (NK) cells by inhibiting the SHIP1 enzyme, offering new therapeutic approaches to treat cancers and infectious diseases.

Background:
Natural killer (NK) cells play a vital role in the body's innate immune defense, targeting and eliminating tumor cells and infected cells. However, their activity can be suppressed in various diseases, limiting their effectiveness. The discovery that SHIP1, an enzyme regulating immune cell function, negatively influences NK cell activation prompted research into inhibiting SHIP1 to restore or enhance NK cell responses. This approach aims to overcome immune suppression in diseases such as cancer and viral infections, where enhancing the body's natural defenses can improve therapeutic outcomes.

Technology Overview:
This technology centers on the inhibition of SHIP1 (SH2-domain containing inositol 5'-phosphatase) to activate NK cells broadly and efficiently. By blocking SHIP1 activity, the technology removes an inhibitory checkpoint, allowing NK cells to become more active against disease targets like tumors and infected cells. The patent describes various SHIP1 inhibitors, including small molecule compounds such as 3-alpha-aminocholestane (3AC), alongside genetic methods like RNA interference to reduce SHIP1 expression. These approaches increase NK cell cytotoxicity, which has been validated through experimental studies demonstrating enhanced tumor rejection in animal models. Additionally, the technology covers multiple pharmaceutical formulations suitable for clinical administration, including oral, injectable, and transdermal delivery systems. This flexibility supports different treatment regimens and patient needs. The innovation lies in both the identification of SHIP1 as a key regulator of NK cell activity and the application of its inhibition as a therapeutic strategy, providing a novel means to harness innate immunity in fighting diseases.

https://suny.technologypublisher.com/files/sites/adobestock_463012321.jpeg
Photo for reference only, not a depiction of the invention.

Advantages:
•   Broad activation of NK cells through a targeted mechanism, enhancing the body’s natural immune response.
•   Effective against multiple disease types, including cancers and viral infections.
•   Use of both small molecule inhibitors and genetic methods allows for versatile therapeutic strategies.
•   Validated by experimental data showing increased NK cell activity and tumor rejection in preclinical models.
•   Multiple pharmaceutical formulations enable adaptable administration routes for patient convenience.
•   Potential to improve outcomes where current treatments relying on immune activation are limited.

Applications:
•   Treatment of various cancers by stimulating NK cell-mediated tumor cell destruction.
•   Therapeutic intervention in viral infections through enhanced innate immune clearance.
•   Potential use in other diseases where NK cell activity is beneficial to host defense.
•   Integration into combination therapies to boost immune responses alongside existing treatments.
•   Development of pharmaceutical products targeting immune modulation for personalized medicine.

Intellectual Property Summary:
Issued patent, 10,702,538

Stage of Development:
TRL 3 – Experimental proof of concept

Licensing Status:
This technology is available for licensing.

CliniAI - Autonomous Triage Diagnostic Flow Enabled by Knowledge Graphs and Conversational AI

JianlingL@tla.arizona.edu — Mon, 15 Jun 2026 16:01:50 GMT

CliniAI is a multi-lingual AI-powered system that gives patients access to medical triage and diagnostic guidance through a conversational interface, without requiring an in-person visit or real-time telehealth meeting. Patients describe their symptoms, answer follow-up questions to help with diagnostic triage flow, and receive a list of possible conditions along with recommended next steps. The software was developed to pair with health kiosks to provide patients in rural areas with an initial diagnosis when wait times for a primary care provider or telehealth appointment are long. CliniAI has been trained on PubMed data and has guardrails to differentiate information sources which provides more confidence in scoring for various diseases as opposed to methods for simple context matching based on responses. CliniAI can also be customized with proprietary data from a provider for specific diagnostic flows.

Background:
The average wait time for a primary care medical appointment in the United States is 30 days, and in rural areas the problem is significantly worse due to provider shortages and geographic barriers. Patients in these communities often have no practical option for timely care short of driving long distances or visiting an ER for non-emergency issues, which contributes to overcrowding on an already stretched healthcare system. Telehealth platforms are an alternative, but they still depend on provider availability and require patients to have a smartphone or computer with a reliable internet connection. Existing health chatbots attempt to fill this gap but provide general information rather than a guided evaluation and lack safeguards to handle emergencies or ensure the guidance they give is grounded in verified medical sources. CliniAI is designed to address these gaps and enable access in locations where traditional digital health tools simply cannot reach to quickly provide medical triage help.

Applications:

Medical triage assistance
Rural healthcare
Urgent care
Telehealth platforms
Hospital systems

Advantages:

Can be integrated with health kiosks or used standalone
24/7 availability
Multi-lingual support
Conversational interface
Model is grounded in verified health knowledge sources
Customizable for healthcare providers

Image-Based Soft-Sensor Approach to Automate Microfluidic Control

lbricha@upenn.edu — Mon, 15 Jun 2026 13:59:06 GMT

Leveraging open-source AI platforms, this technology enables automated image-based detection, prediction, and control of microfluidic single bubble/droplet formation.
Problem:
Given the incorporation of microfluidic bubble/droplet generation in many applications of science and medicine, improving their high-quality throughout with minimal human intervention is crucial. There is currently a lack of tools available to automate microfluidic control, which is critical to decrease dependency on human expertise and scale the overall throughput and implementation of microfluidic devices.
Solution:
To maximize the capabilities of microfluidic technologies, the inventors develop a two-step soft-sensor (virtual-sensor) and respond strategy to enable an autonomous microfluidic system using a combination of image-based AI and air pressure control to correct droplet formation.
Technology:
To decrease the levels of necessary human intervention, this technology leverages open-source AI softwares to develop a convolutional neural network (CNN) trained on thousands of images to predict and correct aberrant droplet formations. This is achieved using a two-step soft-sensor approach that queries the droplet formation using a high-speed camera and implements an image recognition algorithm and CNN for feature extraction. These inform the proportional-integral-derivative (PID) controller to establish set-point tracking and rejection with direct air pressure modulation at the site of droplet formation on the device to achieve long-term droplet stability with minimal human intervention.
Advantages:

CNN was trained on 40,000+ 128 x 600 resolution images and validated on 4,800+ images.
CNN accuracy tests reveal 100% accuracy out of 450 images of novel test data (outside of the validation set).
Image algorithm incorporates an assessment of the (1) flow rate, (2) size, and (3) uniformity of the bubbles/droplets formed.
PID Feedback Control (in response to CNN detection) is enabled using either aqueous flow rate or gas pressure to maintain the desired bubble/droplet size setpoint.
This system demonstrates robust disturbance rejection, enabling over 99.2% (compared to 2.16% without the controller) of bubbles produced being within 5% of the setpoint value over an 8-hour production time.

Stage of Development:

Proof of Concept
Bench Prototype

Control schematic using CNN & image recognition for PID control of microfluidic bubble generation. The high-speed camera senses and relays the droplet size and shape, which is then fed through the CNN and overlayed onto the desired set point. The discrepancy is then used to compute the amount of pressure needed to be increased or decreased through the PID in order to maintain the set-point.
Intellectual Property:

PCT Pending

Reference Media:

Land, O et al.; Chem Eng J, 2024 Nov 1; 499: 156494.

Desired Partnerships:

License
Co-development

Docket # 24-10736

Filter Cell

cabrigo@usf.edu — Mon, 15 Jun 2026 13:57:30 GMT

Advantages

Accurately mirrors real world filter performance so results are truly reliable
Cuts research time, costs, and resources significantly across the entire process
Runs hundreds of tests simultaneously in a surprisingly compact laboratory space
Modular and printable design makes scaling fast, simple, and cost effective

Summary

Safe drinking water depends on activated carbon block filters, yet the tools to rigorously test them are fundamentally broken. Current methods are resource intensive, demanding significant time, space, and water. Critically, no small-scale approach can accurately replicate the unique structural dynamics of these filters. Researchers and developers are left with no efficient path forward, forcing costly full-scale studies that slow innovation and delay public health solutions.

This modular filter cell solves what was previously unsolvable: accurately downscaling activated carbon block filters for laboratory evaluation. Unlike past attempts that simply adjusted flow rates, this apparatus replicates the true outside in flow path by using an ACB puck that mirrors the carbon thickness of a full-scale filter and normalizes flow by surface area. The result is a device that integrates into multi cell rigs, enabling high throughput parallel testing of hydraulic residence times, biofilm development, and contaminant removal, all in a fraction of the footprint.

Schematic of the full-size ACB filter and the filter cell design.

Desired Partnerships:

License
Sponsored Research
Co-Development

Top Feed Inclined Rotary Gasifier

IEA@rfsuny.org — Mon, 15 Jun 2026 13:27:33 GMT

The Top Feed Inclined Rotary Gasifier is a simple, lightweight, and low-cost device that uses gravity to feed materials for gasification, producing syngas for direct combustion—making energy generation more reliable, affordable, and accessible for various applications.

Background:
Gasification is a thermochemical process that converts organic or fossil-based carbonaceous materials into syngas, a mixture of carbon monoxide, hydrogen, and carbon dioxide. This technology has gained increasing attention as a versatile solution for energy generation, waste management, and the production of chemicals and fuels from a wide range of feedstocks, including biomass, municipal solid waste, and coal. The growing demand for sustainable and decentralized energy systems, coupled with the need to reduce reliance on landfilling and fossil fuels, has driven interest in gasification. However, widespread adoption is often hindered by the technical and economic barriers associated with existing gasification systems, particularly for small-scale or distributed applications. Current gasification technologies typically involve complex mechanical systems for feedstock handling, intricate reactor designs, and extensive gas cleaning and conditioning stages. These systems are often expensive to build and operate, requiring significant capital investment and specialized maintenance. Mechanical feeding mechanisms can be prone to jamming or wear, especially when processing heterogeneous or bulky feedstocks, leading to operational downtime and increased maintenance costs. Additionally, the complexity of these systems can limit their reliability and accessibility, particularly in remote or resource-limited settings where technical expertise and spare parts may be scarce. As a result, many potential users—such as small industries, agricultural operations, or communities seeking on-site waste-to-energy solutions—find conventional gasifiers impractical or unaffordable, restricting the broader deployment of gasification technology.

Technology Overview:
The Top Feed Inclined Rotary Gasifier is a streamlined gasification system designed to convert solid feedstocks into syngas for direct combustion. Its defining features include an inclined rotary chamber that receives feedstock from the top via gravity, eliminating the need for complex mechanical feeding systems. As the material progresses through the rotating chamber, it undergoes gasification, and the resulting syngas is routed to a separate burner for immediate combustion. The system is engineered for lightweight construction, simplicity, and low cost, making it easy to manufacture and operate. This approach is intended to enhance reliability and reduce operational challenges, making the technology accessible for a range of users, from industrial facilities to small-scale or distributed energy applications. What differentiates this technology is its focus on operational simplicity and cost-effectiveness without sacrificing performance. By leveraging gravity-fed top loading and minimizing moving parts, the design significantly reduces mechanical complexity and maintenance requirements compared to traditional gasifiers. This not only lowers both initial and ongoing costs but also improves reliability, especially in remote or resource-limited settings where technical support may be scarce. The direct combustion of syngas further streamlines the energy conversion process, eliminating the need for additional gas cleaning or handling stages. These features collectively position the Top Feed Inclined Rotary Gasifier as a practical and scalable solution for waste-to-energy conversion, on-site fuel generation, and other applications where traditional gasification systems may be too expensive or difficult to deploy.

https://suny.technologypublisher.com/files/sites/adobestock_1662247811.jpeg
Photo for reference only, not a depiction of the invention.

Advantages:
•   Reduced mechanical complexity through gravity-fed top entry, enhancing reliability and ease of maintenance
•   Lightweight and simple design lowers manufacturing and operational costs
•   Direct combustion of syngas via a separate burner streamlines energy conversion
•   Improved system dependability suitable for remote or resource-limited environments
•   Accessible and cost-effective for a wide range of applications, including energy generation, waste-to-energy, and on-site fuel production
•   Scalable for small-scale and distributed energy solutions
•   Facilitates easier manufacturing and operation by skilled personnel

Applications:
•   Distributed energy generation systems
•   Waste-to-energy conversion plants
•   On-site industrial fuel production
•   Agricultural biomass energy solutions

Intellectual Property Summary:
Patent Pending

Stage of Development:
TRL 4

Licensing Status:
This technology is exclusively licensed and not available for licensing.

Implantable Hydrocephalus Valves with Non-Invasive Functionality Monitoring

ip@skysonginnovations.com — Fri, 12 Jun 2026 23:56:48 GMT

Invention Description

Monitoring cerebrospinal fluid flow in hydrocephalus patients is essential for ensuring proper valve function and preventing complications. Current monitoring methods are often invasive, intermittent, and unable to provide continuous real-time feedback on valve performance. Detecting valve malfunctions early can be difficult, which could lead to delayed treatment and increased health risks. This creates a need for a reliable, minimally invasive system capable of continuously monitoring cerebrospinal fluid flow inside implanted devices.

Researchers at Arizona State University have developed a fully implantable unidirectional valve system with an integrated wireless sensing module for monitoring valve functionality to detect malfunctions before the manifestation of clinical symptoms. This system wirelessly monitors cerebrospinal fluid flow without requiring internal power sources. Designed for long-term implantation, the system provides continuous, real-time, non-invasive assessment of valve functionality to improve hydrocephalus treatment monitoring and outcomes. Further, the sensing system is compact, lightweight and fully passive so as not to compromise the valve’s mechanical performance.

This non-invasive, cost-effective system provides real-time flow monitoring, giving clinicians a powerful early-warning tool to help manage hydrocephalus.

Potential Applications

Implantable valves and shunt systems for hydrocephalus management
Wireless implantable sensors for neurological disorder treatments
Implantable unidirectional valve requiring long-term flow or pressure monitoring
- Chronic venous insufficiency, Glaucoma drainage, heart valves, stents, bladder, airway valves, esophageal valves, bile duct, etc.
Healthcare solutions aiming to reduce surgical interventions

Benefits and Advantages

Compact, lightweight, passive wireless sensing requires no internal power source and has no interference with valve function
Real-time monitoring of valve function and fluid flow
Selective detection minimizes biological interference
Potential to reduce invasive surgeries and costly imaging procedures
Validated performance under various fluid conditions

Liquid Fueled Variable Firing Rate Satellite Ignition Burner

IEA@rfsuny.org — Fri, 12 Jun 2026 20:14:21 GMT

This technology uses a liquid-fueled pilot device to reliably ignite and control the combustion of synthetic fuel gas in burners, ensuring efficient energy use and low emissions even when gas quality or flow changes.

Background:
The combustion of synthetic fuel gases, particularly those derived from gasification processes, is an increasingly important field in energy production, waste-to-energy conversion, and industrial heating. These synthetic gases offer a way to utilize waste materials and renewable resources, contributing to sustainability and energy diversification. However, the composition and calorific value of synthetic gases can vary significantly depending on feedstock and process conditions. This variability presents a challenge for achieving efficient, stable, and clean combustion, which is essential for meeting stringent emissions regulations and optimizing energy output. As industries seek to transition toward cleaner and more flexible fuel sources, there is a growing need for technologies that can reliably manage the combustion of synthetic gases under fluctuating conditions. Current approaches to igniting and controlling the combustion of synthetic fuel gases often rely on direct ignition systems or pilot burners that use the same or similar gaseous fuels as the main burner. These methods often struggle to provide stable ignition and complete combustion when the synthetic gas has inconsistent composition, low calorific value, or variable flow rates. Incomplete combustion not only reduces energy efficiency but also leads to increased emissions of pollutants such as carbon monoxide, unburned hydrocarbons, and particulates. Moreover, many existing systems cannot dynamically adjust firing rates in response to changing gas quality, resulting in operational inflexibility and potential non-compliance with environmental standards. As a result, there is a significant gap in the market for solutions that can ensure reliable, efficient, and clean combustion of synthetic gases, especially in applications where fuel characteristics are unpredictable.

Technology Overview:
This technology is a specialized pilot device designed to enhance the ignition and combustion control of synthetic fuel gas burners, particularly those using gas derived from gasification processes. The system employs a separate liquid fuel source as a pilot, functioning as a satellite ignition mechanism that enables variable firing rates. This allows for precise regulation of the combustion process, ensuring complete thermal destruction of the synthetic gas and optimizing emissions. The device maintains stable ignition and consistent control even when the composition or flow rate of the synthetic gas fluctuates, which is a common challenge in waste-to-energy, biofuel production, and industrial heating applications. What differentiates this technology is its ability to decouple the ignition process from the main synthetic gas stream by utilizing a liquid-fueled pilot burner. This approach provides a robust solution for handling variable-quality or inconsistent synthetic gases, offering dynamic adjustment of combustion intensity through variable firing rates. Unlike conventional systems that may struggle with fluctuating gas quality, this device ensures reliable and complete combustion, supporting both energy efficiency and stringent emissions compliance. Its design allows for straightforward integration with existing burner systems, making it a valuable retrofit option for industries seeking improved combustion control and operational flexibility.

https://suny.technologypublisher.com/files/sites/adobestock_778681425.jpeg
Photo for reference only, not a depiction of the invention.

Advantages:
•   Ensures complete thermal destruction of synthetic fuel gas, improving energy efficiency.
•   Optimizes emissions, supporting regulatory compliance and environmental protection.
•   Provides stable ignition and combustion control despite fluctuations in synthetic gas composition or flow rate.
•   Enables variable firing rates for precise regulation of the combustion process.
•   Uses a separate liquid fuel pilot source, enhancing reliability and flexibility of ignition.
•   Suitable for integration with existing burner systems, facilitating retrofit applications.
•   Improves operational flexibility in industries using synthetic or variable-quality gaseous fuels.

Applications:
•   Waste-to-energy plant combustion control
•   Biofuel production burner optimization
•   Industrial heating emissions reduction
•   Gasification system retrofitting

Intellectual Property Summary:
Patent Pending

Stage of Development:
TRL 4

Licensing Status:
This technology is licensed.

Methods and Compositions for Prevention and Mitigation of Radiation-Induced Cardiac Injury Using GLP-1 Receptor Agonists

IEA@rfsuny.org — Fri, 12 Jun 2026 20:00:27 GMT

This technology utilizes glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, to prevent and treat radiation-induced cardiac injury, offering a novel medical approach to protect the heart from damages caused by ionizing radiation.

Background:
Radiation-induced heart disease (RIHD) is a serious complication arising from exposure to ionizing radiation, particularly in cancer patients undergoing thoracic radiotherapy and individuals exposed in military or accidental radiation events. Current treatment options for RIHD are limited, with no approved medical countermeasures specifically addressing the prevention or mitigation of cardiac damage caused by radiation. The growing need for effective solutions to protect heart health in such contexts motivated research into potential therapeutic agents that could reduce inflammation, oxidative stress, and fibrosis associated with radiation exposure.

Technology Overview:
This innovation repurposes GLP-1 receptor agonists (GLP-1RAs)—a class of FDA-approved drugs originally designed to treat diabetes—as a novel solution to combat radiation-induced cardiac injury. GLP-1RAs, such as semaglutide, function by activating specific receptors that have beneficial effects beyond glucose regulation, including cardioprotective actions. In preclinical studies using irradiated mouse models, treatment with GLP-1RAs demonstrated significant reductions in cardiac inflammation, oxidative damage, fibrosis, and electrical conduction abnormalities. The method supports both prophylactic administration before radiation exposure and therapeutic intervention after exposure, highlighting versatility in timing and application. The novelty lies in applying GLP-1 receptor modulation specifically for radiation-induced heart injury, a use not previously established in clinical practice. This approach offers a promising pathway for rapid clinical translation due to the existing regulatory approval of GLP-1RAs for other indications. By leveraging established pharmacological agents, the technology addresses a critical unmet medical need with potential for widespread adoption in multiple high-risk settings.

https://suny.technologypublisher.com/files/sites/adobestock_1804088834.jpeg
Photo for reference only, not a depiction of the invention.

Advantages:
•   Repurposes an FDA-approved drug class, allowing faster clinical adoption and regulatory approval.
•   Demonstrated efficacy in reducing inflammation, oxidative stress, fibrosis, and arrhythmias in preclinical models.
•   Effective as both a preventive and post-exposure treatment for radiation-induced cardiac injury.
•   Addresses a significant unmet need for medical countermeasures in clinical oncology, military, and civilian radiation exposure scenarios.
•   Potentially reduces long-term cardiac complications, improving patient outcomes and quality of life.

Applications:
•   Protecting cancer patients undergoing thoracic radiotherapy from radiation-induced heart disease.
•   Medical countermeasure for military personnel exposed to ionizing radiation during deployment.
•   Emergency treatment for civilians exposed to radiation accidents or incidents.
•   Potential adjunct therapy in combination with existing cardiac protective strategies in radiation oncology.

Intellectual Property Summary:
Patent pending.

Stage of Development:
Inquire for more information

Licensing Status:
This technology is available for licensing.

A Fast And Cost-Effective Method For Early Cancer Detection

lbricha@upenn.edu — Fri, 12 Jun 2026 19:40:24 GMT

A quick and inexpensive method to detect cancer early by exponentially amplifying rare and scarce cancer mutations.
Problem:
Early cancer detection is challenging due to the low levels of cancer-indicating mutant DNA compared to healthy, wild-type DNA. The background noise from the substantial amounts of healthy DNA overwhelms mutant signals. Some current approaches include - amplification refractory mutation system (ARMS)-PCR; next generation sequencing (NGS); CRISPR-mediated Ultra-sensitive detection of Target DNA (CUT)-PCR; and dynamic allele-specific hybridization (DASH). These approaches are often unable to enrich the mutant DNA to a high enough level for accurate detection. Furthermore, they are costly and time-intensive, making them impractical for a real-time point-of-care detection setting.
Solution:
Haim H. Bau and his team combined two technologies, CRISPR-Cas9 and isothermal recombinase polymerase amplification (RPA), to develop the Programmable Enzyme-Assisted Selective Exponential Amplification (PASEA) assay. The exponential increase in mutant DNA fraction (MAF) that is achieved compared to the current methods allows for much easier early cancer detection in a shorter period of time.
Technology:
PASEA is inspired by Darwin’s “survival of the fittest” wherein the scarce cancerous mutant DNA fraction with the superior trait is amplified exponentially and quickly dominates the landscape. The wild-type DNA are also amplified, but at a much slower rate since they are detected and cleaved via CRISPR-Cas9. In just 20 minutes, the initially scant mutant DNA can be amplified from 0.01% up to 70% mutant DNA fraction (via RPA), followed by inexpensive Sanger sequencing to determine the genetic sequence of the mutant DNA. The assay can be applied to a microfluidic chip for point-of-care detection if desired.
Advantages:

In 20 min, PASEA enriches MAF 3-222x better than DASH and CUT-PCR (in 60 min) depending on MAF % before enrichment outlined in table:

PASEA is three times faster than DASH and CUT-PCR for incubation times (20 min vs. 60 min)
Can be implemented in real time point-of-care setting
PASEA resulted in same sensitivity and accuracy as ARMS-PCR combined with NGS but lower cost and less time

Stage of Development:

Target Identified

PASEA inspired by Darwin’s theory “survival of the fittest,” combining the CRISPR-Cas9 and RPA technologies to exponentially amplify the mutant DNA fraction for cancer screening.
Intellectual Property:

US Application US20230052289A1

Desired Partnerships:

License
Co-Development (This replaces collaboration or sponsored research)

Docket #21-9723

ON/OFF Image Processing

IEA@rfsuny.org — Fri, 12 Jun 2026 19:37:59 GMT

ONOFF Image Processing is a novel image enhancement method inspired by the human visual system that improves image contrast while preserving critical luminance information.

Background:
Traditional contrast enhancement algorithms often struggle to maintain key luminance details, resulting in loss of information in low luminance regions of the images. Research into the response properties of the human visual cortex and natural scene statistics revealed a potential for more effective image processing techniques that align closely with how the brain perceives contrast and encode luminance. These insights motivated the development of a new method capable of producing clearer, more reliable image enhancements.

Technology Overview:
ONOFF Image Processing is an innovative technique that mimics the brain’s natural mechanism for interpreting visual scenes by separately processing the ON (light) and OFF (dark) components of an image. This approach preserves the information content inherent in both portions while reducing distortions typically introduced by standard algorithms. The method leverages advanced understanding of visual cortex responses to natural images, integrating this knowledge into the image enhancement workflow to better capture contrast variations as the human eye perceives them. Unlike many existing methods, it maintains critical luminance details by balancing enhancement across bright and dark image regions, avoiding the common problem of losing subtle but important dark features with minimal saturation of lighter features. This technique offers simplicity and reproducibility, making it accessible for integration into various image processing systems. Its design enables enhanced reliability in maintaining image quality, making it especially valuable for applications requiring high fidelity and accurate contrast representation.

https://suny.technologypublisher.com/files/sites/adobestock_1117983413.jpeg
Image for demonstration only, not a depiction of the invention.

Advantages:
•   Preserves critical luminance information by separately processing ON and OFF image components.
•   Reduces saturation commonly introduced by traditional contrast enhancement algorithms.
•   Aligns image processing results with human visual perception for more natural and reliable outputs.
•   Simpler and more reproducible without third-party dependencies.
•   Enhances reliability and consistency in image enhancement and compression tasks.

Applications:
•   Surveillance and security cameras requiring improved image clarity in varied lighting conditions.
•   Digital photography and video processing for enhanced visual quality.
•   Optometric device imaging for research and clinical applications.
•   Any image analysis fields demanding reliable and natural contrast enhancement techniques.

Intellectual Property Summary:
Issued patent 12,008,736

Stage of Development:
This technology is at an early validation stage (TRL 3–4), with the ONOFF image processing method developed and demonstrated in laboratory settings to enhance contrast while preserving luminance, and ongoing efforts focused on broader testing and integration into real-world imaging systems.

Licensing Status:
This technology is available for licensing.

Cyclopropane-Rich Ionic Liquid Compositions for High-Performance Fuel Systems

IEA@rfsuny.org — Fri, 12 Jun 2026 19:30:00 GMT

This technology creates renewable, high-energy-density liquid fuels using specially engineered molecules with multiple cyclopropane rings and energetic anions, offering safe, stable, and clean-burning alternatives to petroleum fuels for aviation and transport.

Background:
The field of high-energy-density fuels is critical for sectors such as aviation, rocketry, and long-haul transport, where the limitations of battery technology and electrification render conventional alternatives impractical. These industries are responsible for a significant portion of global greenhouse gas emissions, and the transition to sustainable, high-performance fuels is essential for reducing their environmental impact. Traditional petroleum-based fuels, while offering high energy density and reliable performance, are derived from non-renewable resources and contribute to carbon emissions. There is a growing demand for renewable, safe, and efficient fuel alternatives that can match or surpass the energy content and operational reliability of conventional fuels, especially under the extreme conditions encountered in aerospace and heavy transport applications. Current approaches to high-energy-density fuels face several persistent challenges. Many bio-derived or synthetic alternatives struggle to achieve the energy density required for demanding applications, often falling short of petroleum benchmarks. Conventional high-energy fuels can be volatile, with low flash points that pose safety risks during storage and handling. Additionally, fuels containing unsaturated bonds are prone to oxidative degradation, reducing their shelf life and reliability. The use of fluorinated or sulfonated additives to enhance performance introduces the risk of corrosive and environmentally harmful combustion byproducts. Furthermore, the synthesis of advanced fuel molecules, such as polycyclopropanated compounds, is typically complex, hazardous, and costly, limiting their scalability and practical adoption. These limitations underscore the need for new fuel chemistries that combine high energy density, safety, stability, and sustainability without the drawbacks of current solutions.

Technology Overview:
This technology introduces polycyclopropanated lipid-inspired ionic liquids (PCP-ILs) designed as next-generation high-energy-density fuels for demanding applications such as aviation, rocketry, and long-haul transport. The PCP-ILs are synthesized from renewable, bio-derived fatty acids and feature a unique molecular structure: a 4-cyclopropyl-1,2,3-triazolium cationic headgroup, long saturated alkyl chains (C₁₆ or C₁₈) with up to three cyclopropane rings at specific biomimetic positions, and energetic, nitrogen-rich anions like cyanoborohydride or tricyanomethanide. The modular four-step synthesis—comprising click chemistry, cyclopropanation, quaternization, and anion metathesis—enables precise control over the degree and stereochemistry of cyclopropanation. These compounds achieve energy densities of 40–42 MJ/L, rivaling or surpassing conventional petroleum-based fuels, and exhibit negligible vapor pressure, high thermal and oxidative stability, tunable low-temperature fluidity, and a broad operational temperature range from -90°C to over 300°C. What differentiates this technology is its synergistic molecular design that combines dual cyclopropanation (in both headgroup and side chains) with energetic, fluorine- and sulfur-free anions, resulting in cumulative ring strain and enhanced combustion enthalpy without producing corrosive byproducts. Unlike traditional fuels, PCP-ILs are non-volatile, have high flash points, and maintain liquid form across extreme temperatures, greatly improving safety and reliability. The design is inspired by natural lipid adaptations, ensuring fluidity and stability, and the renewable feedstock base addresses sustainability concerns. The modular synthetic platform allows for systematic optimization of fuel properties by varying chain length, cyclopropane content, and anion selection, making these fuels highly adaptable to specific operational requirements. This combination of high energy density, safety, environmental friendliness, and renewable sourcing positions PCP-ILs as a transformative solution for sectors where electrification is not feasible.

https://suny.technologypublisher.com/files/sites/adobestock_722909759.jpeg
Photo for reference only, not a depiction of the invention.

Advantages:
•   High energy density fuel (40–42 MJ/L), comparable to or exceeding conventional petroleum-based aviation fuels
•   Derived from renewable, bio-based fatty acids, promoting sustainability
•   Exceptional thermal and oxidative stability with wide operational temperature range (-90°C to >300°C)
•   Negligible vapor pressure and high flash point (>150°C), enhancing safety in storage and handling
•   Fluorine- and sulfur-free composition, eliminating corrosive combustion byproducts
•   Tunable low-temperature fluidity to prevent fuel line freezing and maintain performance
•   Modular synthesis allowing precise control over molecular structure and energy properties
•   Biomimetic design inspired by natural lipid fluidity for improved fuel behavior

Applications:
•   Aviation turbine fuel replacement
•   Rocket propellants
•   Long-haul maritime shipping fuel
•   Military high-energy fuel applications
•   Extreme cold-weather fuel systems

Intellectual Property Summary:
Patent Pending

Stage of Development:
TRL 2

Licensing Status:
This technology is available for licensing.

Video-Based Behavioral Analysis to Facilitate Early Autism Diagnosis

IEA@rfsuny.org — Fri, 12 Jun 2026 18:57:26 GMT

This technology uses a mobile app to record children’s behavior at home, then analyzes the videos with AI to help screen for autism early, providing quick, accessible feedback to families and supporting clinicians with objective behavioral data.

Background:
Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition characterized by a wide range of behavioral and communicative challenges. Early identification and intervention are critical for improving long-term outcomes for children with ASD, as timely support can significantly enhance social, cognitive, and adaptive skills. However, the current landscape of ASD diagnosis is hampered by limited access to specialized clinicians, especially in underserved or rural areas, and by the variability in how symptoms present across individuals. As a result, there is a growing demand for accessible, scalable, and objective tools that can facilitate early screening and diagnosis of ASD, ideally within the child’s natural environment and without the need for frequent clinic visits. Despite the recognized importance of early detection, existing approaches to ASD screening and diagnosis are fraught with challenges. Traditional methods often rely on lengthy, in-person assessments conducted by trained professionals, leading to long wait times—sometimes spanning months or even years—for families seeking answers. These delays can cause significant anxiety and missed opportunities for early intervention. Furthermore, current screening tools may lack sensitivity or specificity, particularly when used outside of clinical settings, and are not always adaptable to the diverse ways in which ASD manifests. The reliance on subjective observations and parental reports can introduce bias and variability, while logistical barriers such as travel, cost, and scheduling further limit access to timely and accurate diagnosis.

Technology Overview:
The technology is a comprehensive video-based behavioral analysis system designed to facilitate early screening and diagnosis of autism spectrum disorder (ASD). It empowers parents or caregivers to administer specific behavioral tasks to children in their home environments, capturing these interactions as video data. Utilizing a mobile application, users can easily record and upload videos, which are then analyzed by advanced computer vision and machine learning algorithms. The system quantifies behavioral features observed in the videos, generates a detailed behavioral profile, and estimates the likelihood of ASD. Feedback is delivered directly to families, providing actionable insights and supporting clinicians with quantified, contextual evidence to inform further evaluation or intervention. This technology is differentiated by its integration of artificial intelligence, naturalistic observation, and user-centric mobile design. Unlike traditional ASD screening methods that require specialized clinical settings and often involve long wait times, this solution brings the assessment process into the home, capturing authentic behaviors in familiar contexts. The use of state-of-the-art machine learning models ensures high accuracy and scalability, while the mobile app streamlines data collection and feedback delivery, making the tool accessible to a broad range of users. By providing rapid, objective, and quantified behavioral analysis, the system not only expedites clinical triage but also democratizes access to early ASD screening, addressing a significant unmet need in both healthcare and community settings.

https://suny.technologypublisher.com/files/sites/adobestock_1620115075.jpeg
Photo for reference only, not a depiction of the invention

Advantages:
•   Enables early and accurate screening of autism spectrum disorder (ASD) using video-based behavioral analysis.
•   Allows parents or caregivers to administer behavioral tasks and record videos in natural home environments, increasing comfort and authenticity.
•   Utilizes advanced AI, computer vision, and machine learning to quantify behavioral features and generate detailed behavioral profiles.
•   Provides rapid, actionable feedback to families and supports clinicians with objective, quantified behavioral data.
•   Mobile application streamlines video data acquisition, upload, analysis, and feedback, enhancing accessibility and ease of use.
•   Reduces clinical wait times and costs by expediting triage and prioritizing children for formal evaluation.
•   Scalable and cost-effective solution that broadens access to early ASD diagnostic resources, especially in community and home settings.

Applications:
•   Home-based early autism screening
•   Remote clinical triage support
•   Quantified behavioral data for clinicians
•   Mobile app for caregiver guidance

Intellectual Property Summary:
Patent application filed

Stage of Development:
TRL 3

Licensing Status:
This technology is available for licensing.

Bio Roll-Up: Material and Process Improvements

IEA@rfsuny.org — Fri, 12 Jun 2026 18:47:42 GMT

Bio Roll-Up is a hydrogel technology that creates flat cell sheets which can be triggered to roll into 3D shapes, using layered polymers and additives like gelatin for improved cell attachment, enabling precise, biomimetic tissue engineering applications.

Background:
Tissue engineering and regenerative medicine are rapidly advancing fields that seek to create functional biological tissues for transplantation, disease modeling, and drug testing. Central to these efforts is the ability to fabricate three-dimensional (3D) structures that accurately mimic the architecture and microenvironment of native tissues. Traditional two-dimensional (2D) cell cultures fail to replicate the complex cell-cell and cell-matrix interactions found in vivo, limiting their utility for both research and therapeutic applications. As a result, there is a growing demand for technologies that can transform flat cell sheets into 3D constructs with precise control over geometry, mechanical properties, and cellular compatibility. Hydrogels, with their high water content and tunable properties, have emerged as promising materials for building such tissue-like scaffolds, but reliable methods to assemble them into complex 3D shapes while maintaining cell viability and function remain a significant challenge. Current approaches to creating 3D hydrogel structures often suffer from several limitations. Many fabrication techniques rely on manual manipulation, which can introduce variability and damage delicate cell layers. Others use chemical or physical triggers for self-assembly that lack precise control, leading to premature or incomplete formation of the desired structures. Additionally, ensuring robust adhesion of hydrogel layers during processing is problematic, frequently resulting in detachment or defects that compromise structural integrity. Achieving uniform cell attachment is another persistent issue, as many hydrogels lack the necessary biochemical cues for effective cell adhesion, leading to poor cell viability and function. These challenges highlight the need for improved fabrication methods that offer reliable control over self-assembly, strong layer adhesion, and enhanced cellular compatibility to realize the full potential of engineered 3D tissues.

Technology Overview:
The described technology is a sophisticated platform for fabricating self-assembling, multi-layered hydrogel structures—referred to as Bio Roll-Up—that transform planar cell sheets into three-dimensional (3D) shapes, such as tubes, for tissue engineering applications. The fabrication process involves sequential spin-coating of an adhesion layer, a thermally responsive copolymer layer, and two distinct biolayers onto a silicon wafer. By carefully modulating the acrylic acid (AA) content between the two biolayers the system achieves precise control over differential swelling, enabling the hydrogel structures to remain flat at physiological temperature and rapidly roll up into 3D forms when cooled. To enhance cellular compatibility, gelatin is incorporated into one of the biolayers, resulting in uniform films with improved cell attachment. The process is further optimized through photolithography for precise patterning. What differentiates this technology is its comprehensive integration of material science, microfabrication, and bioengineering to achieve tunable, on-demand 3D hydrogel assembly with high cell compatibility. The ability to precisely control self-assembly timing through both chemical composition and process engineering sets it apart from conventional hydrogel systems, which often lack such temporal and structural control. The innovative approach to incorporating gelatin—by converting it into a finely ground powder for uniform dispersion—addresses a common challenge in hydrogel biofabrication: achieving both structural integrity and optimal cell attachment. Additionally, the platform’s adaptability is underscored by plans to integrate custom peptide polymers, allowing further tuning of swelling, cell adhesion, and pore size to meet specific biomedical needs. This versatility and level of control make the technology particularly valuable for advanced tissue engineering, regenerative medicine, and the creation of biomimetic environments for cell culture and differentiation studies.

https://suny.technologypublisher.com/files/sites/adobestock_1232696309.jpeg
Photo for reference only, not a depiction of the invention.

Advantages:
•   Precise control of self-assembly timing through modulation of acrylic acid concentration in biolayers
•   Improved adhesion and fabrication reliability using an adhesion layer
•   Ability to maintain flat hydrogel structures at physiological temperature and trigger rapid rolling at lower temperature
•   Enhanced cellular attachment and film uniformity by incorporating gelatin into biolayers
•   Scalable and reproducible fabrication process using photolithography and spin-coating techniques
•   Potential for further customization of hydrogel properties via integration of custom peptide polymers
•   Enables creation of 3D biomimetic hydrogel structures suitable for tissue engineering and regenerative medicine applications

Applications:
•   3D tissue engineering scaffolds
•   Regenerative medicine cell delivery
•   Organ-on-chip model fabrication
•   Customizable biomedical implants
•   Controlled drug release systems

Intellectual Property Summary:
Patent pending

Stage of Development:
TRL 4

Licensing Status:
This technology is available for licensing.

BKHI Prototype

IEA@rfsuny.org — Fri, 12 Jun 2026 18:37:59 GMT

A survey instrument is a tool used to collect data and information from people, often through questionnaires or interviews.

Background:
Survey instruments are fundamental tools in the fields of social science, market research, public health, and education, among others. They enable researchers and organizations to systematically collect data on attitudes, behaviors, opinions, and experiences from a target population. The insights gathered through surveys inform decision-making, policy development, and academic research, making accurate and reliable data collection essential. As the demand for evidence-based practices grows, the need for effective survey instruments that can capture nuanced information from diverse populations has become increasingly important. Despite their widespread use, current survey instruments face several significant challenges. Traditional approaches often suffer from issues such as low response rates, sampling bias, and poorly designed questions that can lead to ambiguous or misleading results. Additionally, the rise of digital surveys has introduced new problems, including survey fatigue and concerns about data privacy and security. Many existing instruments lack the flexibility to adapt to different cultural contexts or evolving research needs, resulting in data that may not be generalizable or actionable. These limitations highlight the ongoing need for improved survey methodologies that can enhance data quality and respondent engagement.

Technology Overview:
This technology is a survey instrument designed to systematically collect, measure, and analyze data from individuals or groups. It typically features a structured set of questions, which can be administered in various formats such as paper-based forms, digital questionnaires, or interactive online platforms. The survey instrument is engineered to ensure consistency and reliability in data collection, often incorporating logic branching, automated scoring, and real-time data validation to enhance accuracy. It may also include tools for respondent anonymity, customizable question types, and integration with data analysis software, making it adaptable to a wide range of research contexts including academic studies, market research, and organizational assessments. What differentiates this survey instrument is its emphasis on precision, flexibility, and user experience. Unlike generic data collection tools, it is designed to minimize response bias and maximize data integrity through features like randomized question order, adaptive questioning, and built-in quality checks. Its modular design allows researchers to tailor the instrument to specific study requirements without compromising standardization. Additionally, the seamless integration with analytical tools streamlines the transition from data collection to insight generation, reducing manual effort and potential for error. These attributes make the survey instrument a robust and versatile solution for gathering actionable, high-quality data across diverse applications.

https://suny.technologypublisher.com/files/sites/adobestock_55069943.jpe
Photo for reference only, not a depiction of the invention.

Advantages:
•   Enables systematic data collection
•   Facilitates gathering of quantitative and qualitative information
•   Supports analysis of opinions, behaviors, and demographics
•   Can be customized for diverse research needs
•   Improves accuracy and consistency in data gathering

Applications:
•   Market research data collection
•   Customer satisfaction assessment
•   Employee feedback gathering
•   Academic research surveys
•   Event feedback evaluation

Intellectual Property Summary:
Inquire for patent status

Stage of Development:
TRL 5

Licensing Status:
This technology is available for licensing.

Bioactive Telodendrimer Nanocarrier for Antibiotics Delivery and Immune Modulation

IEA@rfsuny.org — Fri, 12 Jun 2026 18:10:18 GMT

Novel telodendrimer nanoparticles have been developed to enhance the delivery and safety profile of the antibiotic Polymyxin B by improving its stability and reducing toxicity during treatment.

Background:
Polymyxin B (PMB) is a powerful antibiotic used to treat infections caused by Gram-negative bacteria, but its clinical application is limited due to high toxicity, particularly nephrotoxicity, and poor stability in the bloodstream. These challenges prompted research into advanced drug delivery systems that could maintain the antibiotic's effectiveness while minimizing harmful side effects. The need for safer and more effective PMB formulations or other peptide antibiotics is especially critical for treating severe conditions such as sepsis, where controlling both bacterial infection and inflammatory response is essential.

Technology Overview:
This technology employs telodendrimer nanoparticles (TD NPs) featuring polyanionic charges and hydrophobic groups that encapsulate polymyxin B or other peptide antibiotics via electrostatic and hydrophobic interactions. The encapsulation improves PMB’s stability and retention in the bloodstream, allowing for slower drug release and prolonged systemic distribution compared to free PMB. The TD NPs not only deliver PMB effectively but also directly kill Gram-negative bacteria and neutralize septic molecules such as pathogen- and damage-associated molecular patterns (PAMPs and DAMPs), which trigger harmful inflammation. Comprehensive characterization techniques validate the nanoparticle size, stability, and drug loading, while biological testing confirms maintained antibacterial potency, reduced cytotoxicity, and effective immune modulation in vitro. This multifunctional delivery system addresses critical issues of toxicity and instability, positioning it as a promising alternative to conventional PMB therapies for managing infections and sepsis-induced hyperinflammation.

https://suny.technologypublisher.com/files/sites/adobestock_860641498.jpeg
Photo for reference only, not a depiction of the invention.

Advantages:
•   Enhanced stability and controlled release of polymyxin B or other peptide antibiotics, prolonging its therapeutic window.
•   Reduced cytotoxicity, minimizing side effects such as nephrotoxicity associated with free PMB.
•   Effective neutralization of bacterial endotoxins and inflammatory molecules, supporting immune system regulation.
•   Maintains strong antibacterial activity while modulating harmful immune responses related to sepsis.

Applications:
•   Treatment of Gram-negative bacterial infections with improved safety and efficacy.
•   Therapeutic management of sepsis by controlling both infection and the resulting cytokine storm.
•   Potential use in clinical settings requiring systemic antibiotic delivery with reduced toxicity.
•   Platform technology for future nanodrug formulations targeting complex infectious and inflammatory diseases.

Intellectual Property Summary:
Patent application filed

Stage of Development:
TRL 3

Licensing Status:
This technology is available for licensing.

Use of Blood Nitric Oxide Responses as a Biomarker of Obesity and its Associated Conditions, including Allergy and Asthma

IEA@rfsuny.org — Fri, 12 Jun 2026 17:55:38 GMT

This technology offers a novel method for identifying individuals at increased risk for systemic inflammatory disorders, such as asthma, by measuring intracellular nitric oxide synthase expression in specific immune cells.

Background:
Asthma and other systemic inflammatory disorders often present challenges in effective diagnosis and management due to the complexity of underlying immune responses. Standard assessments may not sufficiently predict disease control or progression, particularly in patients exhibiting uncontrolled symptoms. Research has shown that nitric oxide, a signaling molecule involved in inflammation, plays a critical role in asthma pathology. However, directly linking nitric oxide production in immune cells to disease severity and treatment response remained an unmet need prior to this development.

Technology Overview:
This technology centers on detecting inducible nitric oxide synthase (iNOS) expression within CD33+ monocytes derived from peripheral blood mononuclear cells (PBMCs). By using flow cytometry techniques, the method quantifies the presence of CD33+iNOS+ monocytes as a biomarker for systemic inflammation and asthma control status. Elevated levels of these cells correlate strongly with poor asthma control and reduced patient quality of life, providing a measurable indicator of disease severity. Moreover, the technology incorporates a specialized kit containing antibodies targeting CD33 and iNOS, as well as cytokines such as IL-15, IL-18, IFNγ, and vitamin D3. These reagents enable standardized and reproducible testing, facilitating clinical decision-making regarding the necessity for additional therapies. Notably, the method also identifies an association between increased iNOS responses and obesity, highlighting its utility in understanding multifactorial influences on inflammatory disorders. By focusing on intracellular biomarkers within specific immune cell populations, this approach improves the precision of diagnosing and managing asthma and related inflammatory conditions. It allows clinicians to tailor treatments based on an individual's inflammatory profile, enhancing outcomes by targeting uncontrolled disease pathways more effectively.

https://suny.technologypublisher.com/files/sites/adobestock_282270645.jpeg
Photo for reference only, not a depiction of the invention.

Advantages:
•   Provides a measurable biomarker (CD33+iNOS+ monocytes) that correlates directly with asthma control and systemic inflammation.
•   Uses flow cytometry for precise detection, enabling detailed immune profiling from peripheral blood samples.
•   Standardized kits with specific antibodies and cytokines improve reproducibility and ease of clinical implementation.
•   Links obesity-related inflammation with asthma through nitric oxide pathways, allowing for broader patient risk stratification.
•   Supports personalized treatment decisions by identifying patients who may benefit from additional or alternative therapies.

Applications:
•   Clinical diagnosis and monitoring of asthma severity and control status in patients.
•   Identification of individuals at risk for systemic inflammatory disorders through blood-based biomarkers.
•   Guiding personalized therapy decisions, including the adjustment of anti-inflammatory treatments.
•   Research tool for studying the role of nitric oxide and immune cell activity in inflammatory diseases.
•   Potential use in assessing the impact of obesity on asthma and other inflammation-related conditions.

Intellectual Property Summary:
Pending patent: 16/969,093, filed 2/8/2019

Stage of Development:
TRL 3

Licensing Status:
This technology is available for licensing.